Page last updated: 2024-11-09

ipratropium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID657309
CHEMBL ID1621597
CHEMBL ID1740585
CHEBI ID5956
SCHEMBL ID3125
SCHEMBL ID7862886
SCHEMBL ID19665230
SCHEMBL ID19665229
MeSH IDM0014399

Synonyms (27)

Synonym
C07052
60205-81-4
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane
CHEBI:5956 ,
ipratropium ion
DB00332
ipratropium cation
n-isopropylatropine
HMS2089K19
[(1r,5s)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
NCGC00089786-02
CHEMBL1621597
ipatropium bromide
SCHEMBL3125
DTXSID9048437 ,
SCHEMBL7862886
CHEMBL1740585
bdbm228865
us9333195, ipratropium
SCHEMBL19665230
SCHEMBL19665229
8-azoniabicyclo[3.2.1]octane,3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-,(endo,syn)-
BRD-A47449001-004-13-7
[(1s,5r)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
NCGC00022819-04
bdbm50581210
PD039288
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.00080.00000.690210.0000AID1812131
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.00080.00000.54057.7600AID1812117
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Km9.00000.47704.03089.0000AID771319
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID771317Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID771314Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1253959Activity at beta2 adrenoceptor/muscarinic M3 receptor in guinea pig trachea assessed as time required for inhibited electric fileld-stimulated contraction to recover by 25%2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1253962Bronchodilator activity in intratracheally dosed conscious dog assessed as inhibition of methacholine-induced bronchoconstriction administered in micelle solution2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
AID1812133Binding affinity to human M3 receptor membranes assessed as dissociation half life by liquid scintillation counting analysis2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Discovery of M
AID1812132Binding affinity to human M3 receptor membranes assessed as association half life by liquid scintillation counting analysis2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Discovery of M
AID1812131Displacement of [3H]-N-methyl Scopolamine Chloride from human M2 receptor membranes incubated for 2 hrs by scintillation counting analysis2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Discovery of M
AID1864494Inhibition of human OCT3 overexpressed in HEK293 cells assessed as intracellularly accumulation of ASP+ at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1864495Inhibition of OCT3 (unknown origin) overexpressed in HEK293 cells assessed as intracellular accumulation of ASP+ incubated for 2 mins by Analyst AD plate reader method relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1253963Bronchodilator activity in conscious dog assessed as time required to inhibit methacholine-induced bronchoconstriction at 30 ug administered through intratracheally in micelle solution2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
AID771316Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID771315Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1812117Displacement of [3H]-N-methyl Scopolamine Chloride from human M3 receptor membranes incubated for 2 hrs by scintillation counting analysis2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Discovery of M
AID1253950Displacement of [3H]N-methyl scopolamine from human cloned muscarinic M3 receptor assessed as compound dissociation half life by dilution method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
AID771319Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1253957Activity at beta2 adrenoceptor/muscarinic M3 receptor in guinea pig trachea assessed as inhibition of electric fileld-stimulated contraction2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
AID1864497Inhibition of OCT2 mediated (unknown origin) assessed as intracellular accumulation of ASP+ relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864496Inhibition of OCT1 (unknown origin) overexpressed in HEK293 cells assessed as intracellular accumulation of ASP+ measured at 20 uM for 5 mins by Analyst AD plate reader method relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 105.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index105.15 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index184.11 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (105.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (109)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Defining and Treating a New Pediatric Asthma Endotype: Depression-related Asthma Mediated by the Cholinergic Pathway [NCT04617015]Early Phase 140 participants (Actual)Interventional2016-09-09Completed
Ipratropium Bromide Spray as Treatment for Sialorrhea in Children: a Randomized, Double-blind, Placebo-controlled Crossover Study [NCT03747536]Phase 230 participants (Anticipated)Interventional2019-01-01Not yet recruiting
[NCT01136421]Phase 3124 participants (Actual)Interventional2005-01-31Completed
GOLD Stage I COPD: Is it Really a Disease ? Exercise Tolerance, Muscle Function and Response to Bronchodilation in GOLD Stage I COPD Patients [NCT01360788]53 participants (Actual)Observational2009-02-28Completed
A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique. [NCT00267917]Phase 413 participants Interventional2006-01-17Completed
Postmarketing Surveillance (as Per §67(6)AMG [German Drug Law]) of Atrovent® in Chronic Obstructive Pulmonary Disease [NCT02238158]595 participants (Actual)Observational1999-09-30Completed
Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State [NCT02103374]Phase 445 participants (Actual)Interventional2012-01-31Completed
Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Airways Disease [NCT02238132]374 participants (Actual)Observational1998-12-31Completed
A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy [NCT02238210]Phase 4230 participants (Actual)Interventional2002-12-31Completed
A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD. [NCT02172404]Phase 3160 participants (Actual)Interventional2000-10-31Completed
Open Study on the Efficacy and Safety of Combivent® Aerosol (120 mcg Salbutamol Sulfate Plus 20 mcg Ipratropium Bromide) + Spacer, 12 to 24 Puffs, in Adult Patients With Moderate to Severe Asthma Crisis [NCT02182700]Phase 347 participants (Actual)Interventional1998-07-31Terminated
A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on [NCT02182856]Phase 433 participants (Actual)Interventional1998-02-28Completed
A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-bl [NCT02177253]Phase 31,118 participants (Actual)Interventional2002-10-31Completed
Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 [NCT02182479]Phase 3631 participants (Actual)Interventional1998-04-30Completed
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm [NCT02182713]Phase 430 participants (Actual)Interventional1998-05-31Completed
Postmarketing Surveillance Study (as Per §67(6 )AMG [German Drug Law]) of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease [NCT02238184]105 participants (Actual)Observational2001-01-31Completed
Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease [NCT02233881]4,222 participants (Actual)Observational2001-01-31Completed
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease [NCT02296047]22 participants (Actual)Interventional2014-12-31Completed
Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease [NCT02236715]1,039 participants (Actual)Observational1999-09-30Completed
Double-blind, Controlled Trial to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, for 120 Minutes, in Acute Asthmatic Attacks in Young Children [NCT02235428]Phase 43 participants (Actual)Interventional1998-09-30Terminated
Study to Assess Inhaled Drug Distribution in the Distal Lung and Interstitium Using Cryobiopsy Samples From Subjects With Suspected Interstitial Lung Disease Undergoing Cryobiopsy for Clinical Reasons [NCT03136120]8 participants (Actual)Observational2017-11-21Completed
Postmarketing Surveillance Study (as Per §67(6)AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease [NCT02238171]346 participants (Actual)Observational2000-04-30Completed
A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstr [NCT02176200]Phase 33 participants (Actual)Interventional2003-04-30Terminated
A Randomized, Placebo-controlled, Within-device, Double-blind Tri-national Study to Compare the Safety and Efficacy of Berodual® Administered Via the Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide [NCT02173782]Phase 3892 participants (Actual)Interventional1998-02-28Completed
A Single-Dose, Double Blind, Crossover Trial to Determinate the Comparability of Ipratropium Bromide HFA-134a Inhalation Aerosol to the Market Standard, Atrovent® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT02260011]Phase 241 participants (Actual)Interventional2000-10-31Completed
A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstru [NCT00153075]Phase 419 participants Interventional2005-09-26Completed
A Double-blind, Placebo Controlled Trial to Assess the Safety of Two-week Administration of 80 mcg q.i.d. and 160 mcg q.i.d. of Ipratropium Bromide, as Delivered by the RESPIMAT® Device, in Patients With Chronic Obstructive Pulmonary Disease [NCT02236182]Phase 257 participants (Actual)Interventional1998-07-31Completed
Randomized, Parallel-group Trial to Evaluate Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD [NCT04655170]Phase 460 participants (Anticipated)Interventional2020-12-09Recruiting
A Six Month, Randomized, Double-blind (Within Formulation), Multiple Dose Trial to Compare the Safety and Efficacy of 20 mcg and 40 mcg of Ipratropium Bromide, as Delivered by the RESPIMAT Device, to 18 mcg ATROVENT® Inhalation Aerosol (x 2 Puffs) and Res [NCT02177344]Phase 3646 participants (Actual)Interventional1998-08-31Completed
A Randomized, Methodology Study to Investigate the Use of 3He-MRI Lung Ventilation and Proton MRI Perfusion Imaging to Detect Changes in Ventilation Perfusion Relationships in Chronic Obstructive Pulmonary Disease (COPD) Patients; a Proof of Concept Study [NCT02207452]Phase 111 participants (Actual)Interventional2010-08-05Completed
Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease [NCT02233894]526 participants (Actual)Observational2001-02-28Completed
"COPDGene Ancillary Proposal: Symbicort Intervention in Airway Predominant" [NCT01253473]Phase 446 participants (Actual)Interventional2012-04-30Completed
Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD [NCT06040424]Phase 374 participants (Anticipated)Interventional2023-09-28Active, not recruiting
A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus [NCT02872597]Phase 130 participants (Actual)Interventional2016-09-05Completed
Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial [NCT02584738]Phase 4152 participants (Anticipated)Interventional2015-09-30Recruiting
Comparison of 18 mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 mcg) in a Double Blind, Double Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) [NCT02172443]Phase 350 participants (Actual)Interventional2001-06-30Completed
A Randomized, Double-blind Study to Compare the Safety and Efficacy of Berodual® Inhaled Via the Respimat® Device in Two Dosages (50 µg Fenoterol Hydrobromide + 20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide + 10 µg Ipratropium Bromide, 1 Puff [NCT02182505]Phase 3535 participants (Actual)Interventional1998-09-30Completed
A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique [NCT02176187]Phase 33 participants (Actual)Interventional2003-04-30Terminated
Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law] of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease [NCT02238145]660 participants (Actual)Observational1999-01-31Completed
Postmarketing Surveillance Study (as Per §67 (6) AMG [German Drug Law]) of Atrovent® 500µg/2ml Inhalation Solution in Chronic Obstructive Pulmonary Disease [NCT02238197]477 participants (Actual)Observational2001-02-28Completed
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [NCT00583778]141 participants (Actual)Interventional2004-08-31Completed
A Comparison of 18 µg of Tiotropium Inhalation Capsules and Atrovent® Metered Dose Inhaler (2 Puffs of 20 µg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) [NCT02172469]Phase 3215 participants (Actual)Interventional2001-05-31Completed
A Double-blind, Randomised, Two-way Cross-over Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of a Single Additional Dose of 500 µg Ipratropium Bromide Unit Dose Vial Inhaled Via Nebuliser Versus Placebo After 19 Days of Treatment Wi [NCT02172781]Phase 136 participants (Actual)Interventional2001-01-31Completed
Berodual® Respimat® Inhaler Versus Berodual® MA Using HFA (Hydrofluoroalkane) 134a as Propellant in Adult Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Conditions, an Open-label, Crossover Trial Over a 7-week Treatment Period With [NCT02173795]Phase 3245 participants (Actual)Interventional2002-10-31Completed
Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia [NCT00904436]20 participants (Actual)Interventional1999-12-31Completed
Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease [NCT05786950]40 participants (Anticipated)Interventional2023-01-01Recruiting
Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension [NCT02782052]Phase 30 participants (Actual)Interventional2016-07-31Withdrawn(stopped due to Sponsor's decision)
Chronic Obstructive Pulmonary Disease (COPD) Lung Volume and Symptom Scores Following Bronchodilator Therapy Administration by Vibrating Mesh and Standard Jet Nebulisers: A Pilot Comparison Study [NCT02686086]60 participants (Actual)Interventional2016-02-29Completed
The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD [NCT02576626]Phase 440 participants (Actual)Interventional2015-12-31Completed
A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI [NCT00359788]Phase 4349 participants (Actual)Interventional2006-07-31Completed
Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) [NCT04315558]Phase 221 participants (Anticipated)Interventional2020-11-01Recruiting
Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients [NCT00911651]Phase 46 participants (Actual)Interventional2008-06-30Completed
Clinical Study on the Efficacy of Compound Sodium Chlorate and Aminophylline Tablets for Mild to Moderate Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD). [NCT04101500]Phase 4200 participants (Anticipated)Interventional2019-04-01Recruiting
Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD) [NCT00400153]Phase 31,480 participants (Actual)Interventional2006-11-30Completed
Budesonide Inhalation Suspension for Acute Asthma in Children [NCT00393367]Phase 4179 participants (Actual)Interventional2006-12-31Completed
Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease [NCT01019694]Phase 3470 participants (Actual)Interventional2009-11-30Completed
Arg/Arg Genotype and Long Acting Beta Agonists in Asthma. Improved Quality of Care for Patients With Asthma. [NCT00521222]90 participants (Actual)Interventional2007-06-30Completed
ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) [NCT00928746]Phase 3142 participants (Actual)Interventional2009-06-30Completed
Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase 2: Sensitivity of the Step Test and Shuttle Walk to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD [NCT00807534]44 participants (Anticipated)Interventional2008-10-31Completed
[NCT00000568]Phase 30 participants Interventional1984-09-30Completed
A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD. [NCT02542254]Phase 236 participants (Actual)Interventional2015-10-31Completed
Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy [NCT00180843]2 participants (Actual)Interventional2005-09-30Terminated(stopped due to lack of resources research fellow left)
Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchial Obstruction Attending Emergency Services [NCT00460577]Phase 460 participants (Actual)Interventional2007-03-31Completed
Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness [NCT00605410]Phase 412 participants (Actual)Interventional2008-01-31Completed
Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients [NCT01151579]Phase 489 participants (Actual)Interventional2008-12-31Completed
Ipratropium Bromide (Atrovent®) Used to Treat Exercise Induced Laryngeal Obstruction (EILO). An Open Label Pilot Study [NCT02755714]Phase 1/Phase 220 participants (Actual)Interventional2016-06-22Completed
Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma [NCT04167280]Phase 412 participants (Actual)Interventional2019-11-05Completed
Treating Respiratory Emergencies in Children Study [NCT06074185]Phase 2150 participants (Anticipated)Interventional2024-01-01Not yet recruiting
The Effects of Bronchodilators on Exertional Dyspnea and Exercise Performance in Mild Chronic Obstructive Pulmonary Disease (COPD) Patients and Healthy Elderly Subjects. [NCT00202176]Phase 432 participants (Actual)Interventional2005-07-31Completed
Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study [NCT00498251]30 participants (Actual)Interventional2004-09-30Completed
A Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD [NCT05890638]Phase 374 participants (Anticipated)Interventional2023-08-25Recruiting
A Study to Optimise the Propranolol Block Model for Assessment of the Pharmacological Activity of Bronchodilators in Healthy Volunteers. [NCT00549120]Phase 118 participants (Actual)Interventional2007-08-15Completed
Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Uncomplicated Acute Bronchitis. [NCT03738917]Phase 4668 participants (Actual)Interventional2019-02-01Completed
Comparison of 18 mg of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20 mg, Four Times Daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD). [NCT00239434]Phase 3200 participants Interventional2003-06-30Completed
The Acute Bronchodilator Effects of a Single Dose (2 Puffs) of the Shortacting Anticholinergic Ipratropium Bromide (40μg) and the Short-acting Beta-adrenergic Fenoterol (200μg) in Comparison to Placebo on Top of Pharmacodynamic Steady State of Once Daily [NCT00274066]Phase 365 participants Interventional2002-10-31Completed
A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD [NCT00117182]Phase 2140 participants Interventional2005-07-31Completed
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease ( [NCT01331694]76,130 participants (Actual)Observational2009-07-31Completed
Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator in the Treatment of Patients With Obstructive Pulmonary Disease [NCT03271905]10 participants (Anticipated)Interventional2017-04-10Active, not recruiting
[NCT00462540]Phase 3100 participants (Anticipated)Interventional2007-05-31Completed
A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting [NCT00480194]1,000 participants (Anticipated)Observational2006-12-31Completed
A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared [NCT01350128]Phase 2103 participants (Actual)Interventional2011-05-01Completed
Comparison of Parasympathetic Activity in Mild, Moderate, and Severe Asthma With Fixed Airway Obstruction [NCT05550402]60 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Comparison of 18 Mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 Mcg) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) [NCT00274092]Phase 3132 participants (Actual)Interventional2002-09-30Completed
Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease [NCT00296946]Phase 220 participants Interventional2004-11-30Completed
A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation [NCT00273962]Phase 4500 participants (Actual)Interventional2002-05-31Completed
A Comparison of 18 μg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 μg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD). [NCT00274040]Phase 3141 participants Interventional2002-07-31Completed
Effect of Bronchodilators on the Exercise Capacity of Bronchiectasis Patients [NCT05183841]40 participants (Anticipated)Interventional2022-04-14Enrolling by invitation
Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD [NCT01655199]40 participants (Anticipated)Interventional2012-09-30Recruiting
A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease [NCT03064113]Phase 232 participants (Actual)Interventional2011-05-31Completed
Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population [NCT01337336]1 participants (Actual)Observational2010-10-31Completed
The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia [NCT01987219]Phase 315 participants (Actual)Interventional2013-03-31Completed
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes [NCT01691079]Phase 420 participants (Actual)Interventional2012-12-31Completed
An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT02236169]Phase 230 participants (Actual)Interventional2000-10-31Completed
Bronchodilator Effect on O2 Deficit and V'O2 Kinetics During Moderate Intensity Exercise in Normoxemic COPD. [NCT00354354]Phase 412 participants (Actual)Interventional2006-03-31Completed
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently P [NCT00388882]Phase 4327 participants (Actual)Interventional2006-10-04Completed
Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide [NCT00381589]25 participants (Anticipated)Interventional2006-10-31Completed
A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects With Chronic Obstructive Pulmonary Disease [NCT01691482]Phase 456 participants (Actual)Interventional2012-07-23Completed
Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease [NCT00371527]200 participants Interventional2002-10-31Completed
Preliminary Study for Comparison of Triple Therapy Nebulizer Versus Dry Powdered Inhaler for Care Transitions in COPD [NCT03219866]Phase 440 participants (Actual)Interventional2017-10-03Terminated(stopped due to Lower enrollment than Sponsor expected - Sponsor stopped study)
A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma. [NCT03296579]100 participants (Anticipated)Interventional2018-06-30Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD [NCT01426009]Phase 2140 participants (Actual)Interventional2011-08-31Completed
Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial [NCT00588406]Phase 395 participants (Actual)Interventional2007-09-30Completed
SAPS:Smoking Asthmatics Pilot Study: [NCT01696214]Phase 420 participants (Actual)Interventional2012-10-31Completed
Glittre Activities of Daily Life-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD) [NCT03071731]34 participants (Anticipated)Interventional2017-04-13Recruiting
Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial. [NCT01943552]Phase 4192 participants (Actual)Interventional2013-10-31Completed
Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophyll [NCT01415518]Phase 4581 participants (Actual)Interventional2011-09-01Completed
Randomized Control Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children [NCT02458482]0 participants (Actual)Interventional2015-07-31Withdrawn(stopped due to The trainee for whom I designed the study did not begin enrollment and has left our institution.)
A Single Center Study to Measure the Bronchodilator Effect of Albuterol Sulfate or Albuterol Sulfate/Ipratropium Bromide Using the Pneuma Respiratory Inhaler and the ProAir HFA Inhaler in Stable COPD Patients [NCT03480997]Phase 146 participants (Actual)Interventional2016-12-27Completed
Comparison of Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination Delivered Via pMDI and Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol in Patients With Stable Moderate-Severe-Very Severe Chro [NCT04446637]Phase 30 participants (Actual)Interventional2021-09-03Withdrawn(stopped due to administrative decision)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00359788 (114) [back to overview]FEV1 at 1 Hour at Week 12
NCT00359788 (114) [back to overview]Physician Global Evaluation
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1
NCT00359788 (114) [back to overview]Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12
NCT00359788 (114) [back to overview]Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6
NCT00359788 (114) [back to overview]Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1
NCT00359788 (114) [back to overview]Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12
NCT00359788 (114) [back to overview]Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6
NCT00359788 (114) [back to overview]Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1
NCT00359788 (114) [back to overview]Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks
NCT00359788 (114) [back to overview]Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 1
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 10
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 11
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 12
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 2
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 3
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 4
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 5
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 6
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 7
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 8
NCT00359788 (114) [back to overview]Day Time Albuterol Use During Week 9
NCT00359788 (114) [back to overview]Evening PEFR at Week 1
NCT00359788 (114) [back to overview]Evening PEFR at Week 10
NCT00359788 (114) [back to overview]Evening PEFR at Week 11
NCT00359788 (114) [back to overview]Evening PEFR at Week 12
NCT00359788 (114) [back to overview]Evening PEFR at Week 2
NCT00359788 (114) [back to overview]Evening PEFR at Week 3
NCT00359788 (114) [back to overview]Evening PEFR at Week 4
NCT00359788 (114) [back to overview]Evening PEFR at Week 5
NCT00359788 (114) [back to overview]Evening PEFR at Week 6
NCT00359788 (114) [back to overview]Evening PEFR at Week 7
NCT00359788 (114) [back to overview]Evening PEFR at Week 8
NCT00359788 (114) [back to overview]Evening PEFR at Week 9
NCT00359788 (114) [back to overview]FEV1 at -10 Minutes at Week 12
NCT00359788 (114) [back to overview]FEV1 at -10 Minutes at Week 6
NCT00359788 (114) [back to overview]Morning Peak Expiratory Flow Rate (PEFR) at Week 1
NCT00359788 (114) [back to overview]FEV1 at 1 Hour at Week 6
NCT00359788 (114) [back to overview]FEV1 at 1 Hour on Day 1
NCT00359788 (114) [back to overview]FEV1 at 15 Minutes at Week 12
NCT00359788 (114) [back to overview]FEV1 at 15 Minutes at Week 6
NCT00359788 (114) [back to overview]FEV1 at 15 Minutes on Day 1
NCT00359788 (114) [back to overview]FEV1 at 2 Hours at Week 12
NCT00359788 (114) [back to overview]FEV1 at 2 Hours at Week 6
NCT00359788 (114) [back to overview]FEV1 at 2 Hours on Day 1
NCT00359788 (114) [back to overview]FEV1 at 3 Hours at Week 12
NCT00359788 (114) [back to overview]FEV1 at 3 Hours at Week 6
NCT00359788 (114) [back to overview]FEV1 at 3 Hours on Day 1
NCT00359788 (114) [back to overview]FEV1 at 30 Minutes at Week 12
NCT00359788 (114) [back to overview]FEV1 at 30 Minutes at Week 6
NCT00359788 (114) [back to overview]FEV1 at 30 Minutes on Day 1
NCT00359788 (114) [back to overview]FEV1 at 4 Hours at Week 12
NCT00359788 (114) [back to overview]FEV1 at 4 Hours at Week 6
NCT00359788 (114) [back to overview]FEV1 at 4 Hours on Day 1
NCT00359788 (114) [back to overview]FEV1 at 6 Hours at Week 12
NCT00359788 (114) [back to overview]FEV1 at 6 Hours at Week 6
NCT00359788 (114) [back to overview]FEV1 at 6 Hours on Day 1
NCT00359788 (114) [back to overview]FVC at -10 Minutes at Week 12
NCT00359788 (114) [back to overview]FVC at -10 Minutes at Week 6
NCT00359788 (114) [back to overview]FVC at 1 Hour at Week 12
NCT00359788 (114) [back to overview]FVC at 1 Hour at Week 6
NCT00359788 (114) [back to overview]FVC at 1 Hour on Day 1
NCT00359788 (114) [back to overview]FVC at 15 Minutes at Week 12
NCT00359788 (114) [back to overview]FVC at 15 Minutes at Week 6
NCT00359788 (114) [back to overview]FVC at 15 Minutes on Day 1
NCT00359788 (114) [back to overview]FVC at 2 Hours at Week 12
NCT00359788 (114) [back to overview]FVC at 2 Hours at Week 6
NCT00359788 (114) [back to overview]FVC at 2 Hours on Day 1
NCT00359788 (114) [back to overview]FVC at 3 Hours at Week 12
NCT00359788 (114) [back to overview]FVC at 3 Hours at Week 6
NCT00359788 (114) [back to overview]FVC at 3 Hours on Day 1
NCT00359788 (114) [back to overview]FVC at 30 Minutes at Week 12
NCT00359788 (114) [back to overview]FVC at 30 Minutes at Week 6
NCT00359788 (114) [back to overview]FVC at 30 Minutes on Day 1
NCT00359788 (114) [back to overview]FVC at 4 Hours at Week 12
NCT00359788 (114) [back to overview]FVC at 4 Hours at Week 6
NCT00359788 (114) [back to overview]FVC at 4 Hours on Day 1
NCT00359788 (114) [back to overview]FVC at 6 Hours at Week 12
NCT00359788 (114) [back to overview]FVC at 6 Hours at Week 6
NCT00359788 (114) [back to overview]FVC at 6 Hours on Day 1
NCT00359788 (114) [back to overview]Morning PEFR at Week 10
NCT00359788 (114) [back to overview]Morning PEFR at Week 11
NCT00359788 (114) [back to overview]Morning PEFR at Week 12
NCT00359788 (114) [back to overview]Morning PEFR at Week 2
NCT00359788 (114) [back to overview]Morning PEFR at Week 3
NCT00359788 (114) [back to overview]Morning PEFR at Week 4
NCT00359788 (114) [back to overview]Morning PEFR at Week 5
NCT00359788 (114) [back to overview]Morning PEFR at Week 6
NCT00359788 (114) [back to overview]Morning PEFR at Week 7
NCT00359788 (114) [back to overview]Morning PEFR at Week 8
NCT00359788 (114) [back to overview]Morning PEFR at Week 9
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 1
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 10
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 11
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 12
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 2
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 3
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 4
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 5
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 6
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 7
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 8
NCT00359788 (114) [back to overview]Night Time Albuterol Use During Week 9
NCT00359788 (114) [back to overview]Patient Global Evaluation
NCT00359788 (114) [back to overview]Patient Global Evaluation
NCT00359788 (114) [back to overview]Physician Global Evaluation
NCT00393367 (12) [back to overview]Mean Change in Asthma Score at 2 Hours
NCT00393367 (12) [back to overview]Change in Mean Heart Rate
NCT00393367 (12) [back to overview]Mean Change in Respiratory Rate.
NCT00393367 (12) [back to overview]Median Change in Asthma Score 2 Hours After Intervention
NCT00393367 (12) [back to overview]Number of Patients Hospitalized
NCT00393367 (12) [back to overview]Number of Subjects Moving From the Severe Asthma to Mild Asthma Category
NCT00393367 (12) [back to overview]Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category
NCT00393367 (12) [back to overview]Number of Subjects Remaining in the Severe Asthma Category
NCT00393367 (12) [back to overview]Oxygen Saturation.
NCT00393367 (12) [back to overview]Relapse / Readmission Numbers.
NCT00393367 (12) [back to overview]Number of Participants With Adverse Events (Non-serious).
NCT00393367 (12) [back to overview]Serious Adverse Events
NCT00400153 (78) [back to overview]Duration of Therapeutic FEV1 Response at Day 57
NCT00400153 (78) [back to overview]Duration of Therapeutic FEV1 Response at Day 85
NCT00400153 (78) [back to overview]FEV1 AUC0-4 at Day 1
NCT00400153 (78) [back to overview]FEV1 AUC0-4 at Day 29
NCT00400153 (78) [back to overview]FEV1 AUC0-4 at Day 57
NCT00400153 (78) [back to overview]FEV1 AUC0-4 at Day 85
NCT00400153 (78) [back to overview]FEV1 AUC0-6 at Day 1
NCT00400153 (78) [back to overview]FEV1 AUC0-6 at Day 29
NCT00400153 (78) [back to overview]FEV1 AUC0-6 at Day 57
NCT00400153 (78) [back to overview]FEV1 AUC0-6 at Day 85
NCT00400153 (78) [back to overview]FEV1 AUC4-6 at Day 1
NCT00400153 (78) [back to overview]FEV1 AUC4-6 at Day 29
NCT00400153 (78) [back to overview]FEV1 AUC4-6 at Day 57
NCT00400153 (78) [back to overview]FEV1 AUC4-6 at Day 85
NCT00400153 (78) [back to overview]FVC AUC0-4 at Day 1
NCT00400153 (78) [back to overview]FVC AUC0-4 at Day 29
NCT00400153 (78) [back to overview]FVC AUC0-4 at Day 57
NCT00400153 (78) [back to overview]FVC AUC0-4 at Day 85
NCT00400153 (78) [back to overview]FVC AUC0-6 at Day 1
NCT00400153 (78) [back to overview]FVC AUC0-6 at Day 29
NCT00400153 (78) [back to overview]FVC AUC0-6 at Day 57
NCT00400153 (78) [back to overview]FVC AUC0-6 at Day 85
NCT00400153 (78) [back to overview]FVC AUC4-6 at Day 1
NCT00400153 (78) [back to overview]FVC AUC4-6 at Day 29
NCT00400153 (78) [back to overview]FVC AUC4-6 at Day 57
NCT00400153 (78) [back to overview]FVC AUC4-6 at Day 85
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably
NCT00400153 (78) [back to overview]Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler
NCT00400153 (78) [back to overview]Night-time Rescue Medication Use
NCT00400153 (78) [back to overview]Night-time Symptom Score
NCT00400153 (78) [back to overview]Noncompartmental Parameters of Albuterol at Steady State
NCT00400153 (78) [back to overview]Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State
NCT00400153 (78) [back to overview]Peak FEV1 Response at Day 1
NCT00400153 (78) [back to overview]Peak FEV1 Response at Day 29
NCT00400153 (78) [back to overview]Peak FEV1 Response at Day 57
NCT00400153 (78) [back to overview]Peak FEV1 Response at Day 85
NCT00400153 (78) [back to overview]Peak FVC Response at Day 1
NCT00400153 (78) [back to overview]Peak FVC Response at Day 29
NCT00400153 (78) [back to overview]Peak FVC Response at Day 57
NCT00400153 (78) [back to overview]Peak FVC Response at Day 85
NCT00400153 (78) [back to overview]Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period
NCT00400153 (78) [back to overview]Physician's Global Evaluation Score on Pulmonary Function Testing Day 29
NCT00400153 (78) [back to overview]Physician's Global Evaluation Score on Pulmonary Function Testing Day 57
NCT00400153 (78) [back to overview]Physician's Global Evaluation Score on Pulmonary Function Testing Day 85
NCT00400153 (78) [back to overview]Rescue Medication Use on Pulmonary Test Day 1
NCT00400153 (78) [back to overview]Rescue Medication Use on Pulmonary Test Day 29
NCT00400153 (78) [back to overview]Rescue Medication Use on Pulmonary Test Day 57
NCT00400153 (78) [back to overview]Rescue Medication Use on Pulmonary Test Day 85
NCT00400153 (78) [back to overview]Time to Onset of Therapeutic FEV1 Response at Day 1
NCT00400153 (78) [back to overview]Time to Onset of Therapeutic FEV1 Response at Day 29
NCT00400153 (78) [back to overview]Time to Onset of Therapeutic FEV1 Response at Day 57
NCT00400153 (78) [back to overview]Time to Onset of Therapeutic FEV1 Response at Day 85
NCT00400153 (78) [back to overview]Time to Peak FEV1 Response at Day 1
NCT00400153 (78) [back to overview]Time to Peak FEV1 Response at Day 29
NCT00400153 (78) [back to overview]Time to Peak FEV1 Response at Day 57
NCT00400153 (78) [back to overview]Time to Peak FEV1 Response at Day 85
NCT00400153 (78) [back to overview]Trough Peak Expiratory Flow Rate (PEFR)
NCT00400153 (78) [back to overview]Device Preference (Respimat or MDI)
NCT00400153 (78) [back to overview]Frequency Distribution of Satisfaction Rating With Inhaler Attributes
NCT00400153 (78) [back to overview]Rating of Action of Turning Clear Base of Respimat
NCT00400153 (78) [back to overview]COPD Exacerbation During the On-treatment Period
NCT00400153 (78) [back to overview]COPD Exacerbation Rate During the On-treatment Period
NCT00400153 (78) [back to overview]Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-2 Hours
NCT00400153 (78) [back to overview]Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-6 Hours
NCT00400153 (78) [back to overview]Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-2 Hours
NCT00400153 (78) [back to overview]Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-6 Hours
NCT00400153 (78) [back to overview]Daytime Rescue Medication Use
NCT00400153 (78) [back to overview]Daytime Symptom Score
NCT00400153 (78) [back to overview]Duration of Therapeutic FEV1 Response at Day 1
NCT00400153 (78) [back to overview]Duration of Therapeutic FEV1 Response at Day 29
NCT00460577 (5) [back to overview]Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation
NCT00460577 (5) [back to overview]Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation
NCT00460577 (5) [back to overview]Mean Change in Pulse Oxymetry From Baseline to Final Evaluation
NCT00460577 (5) [back to overview]Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation
NCT00460577 (5) [back to overview]Pharmacoeconomic Analysis
NCT00521222 (5) [back to overview]Absolute Change in Morning Peak Flow
NCT00521222 (5) [back to overview]Change in Asthma Symptom Score
NCT00521222 (5) [back to overview]Change in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted Pre-Bronchodilator
NCT00521222 (5) [back to overview]Change in Forced Expiratory Volume in 1 Second (FEV1) Post-Bronchodilator
NCT00521222 (5) [back to overview]Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-Bronchodilator
NCT00583778 (2) [back to overview]Change in FEV-1 % Predicted Over Time
NCT00583778 (2) [back to overview]Number of Participants With Bronchodilation
NCT00588406 (2) [back to overview]Hospitalization
NCT00588406 (2) [back to overview]FEV1 Percent Predicted
NCT00928746 (17) [back to overview]Actuations Recorded on Patient Diary
NCT00928746 (17) [back to overview]Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Actuations Based on Advancing the Actuation Indicator
NCT00928746 (17) [back to overview]Actuations Dispensed
NCT00928746 (17) [back to overview]Actuations Registered by the Actuation Indicator
NCT00928746 (17) [back to overview]Actuations Registered by the Actuation Indicator and Read by Site Coordinator
NCT00928746 (17) [back to overview]Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed
NCT00928746 (17) [back to overview]Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed
NCT00928746 (17) [back to overview]Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed
NCT00928746 (17) [back to overview]Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed
NCT00928746 (17) [back to overview]Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire
NCT00928746 (17) [back to overview]Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire
NCT01019694 (39) [back to overview]Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36
NCT01019694 (39) [back to overview]Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 0
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 12
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 24
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 3
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 36
NCT01019694 (39) [back to overview]Physician's Global Evaluation at Week 48
NCT01019694 (39) [back to overview]Change From Baseline in FVC at Week 48
NCT01019694 (39) [back to overview]Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization
NCT01019694 (39) [back to overview]Change From Baseline in FEV1 at Day 1
NCT01019694 (39) [back to overview]Change From Baseline in FEV1 at Week 12
NCT01019694 (39) [back to overview]Change From Baseline in FEV1 at Week 24
NCT01019694 (39) [back to overview]Change From Baseline in FEV1 at Week 48
NCT01019694 (39) [back to overview]Change From Baseline in FVC at Day 1
NCT01019694 (39) [back to overview]Change From Baseline in FVC at Week 12
NCT01019694 (39) [back to overview]Change From Baseline in FVC at Week 24
NCT01019694 (39) [back to overview]Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36
NCT01019694 (39) [back to overview]Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36
NCT01019694 (39) [back to overview]Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36
NCT01019694 (39) [back to overview]Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48
NCT01019694 (39) [back to overview]Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12
NCT01019694 (39) [back to overview]Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3
NCT01019694 (39) [back to overview]Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24
NCT01151579 (3) [back to overview]Total Number of Participants With Arrhythmias
NCT01151579 (3) [back to overview]Arrhythmias
NCT01151579 (3) [back to overview]Heart Rate in Beats Per Minute
NCT01331694 (2) [back to overview]Average Annual Adjusted Post-Index COPD-Related Costs
NCT01331694 (2) [back to overview]Time to First Chronic Obstructive Pulmonary Disease (COPD) Event
NCT01337336 (4) [back to overview]Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation
NCT01337336 (4) [back to overview]Mean Annual COPD-related Costs Per Participant
NCT01337336 (4) [back to overview]Number of Participants With the Indicated COPD-related Exacerbations
NCT01337336 (4) [back to overview]Number of the Indicated COPD-related Exacerbations
NCT01350128 (9) [back to overview]Peak Change From Baseline in IC on Day 7
NCT01350128 (9) [back to overview]Proportion of Subjects Achieving at Least 12% Improvement in FEV1 on Day 1
NCT01350128 (9) [back to overview]Time to Onset of Action ( ≥10% Improvement in FEV1) on Day 1
NCT01350128 (9) [back to overview]Change From Baseline in 12-hour Post-dose Trough FEV1 on Day 7
NCT01350128 (9) [back to overview]Change From Baseline in Morning Pre-dose FEV1 on Day 7
NCT01350128 (9) [back to overview]FEV1 AUC0-12
NCT01350128 (9) [back to overview]Peak Change From Baseline in FEV1 on Day 1
NCT01350128 (9) [back to overview]Peak Change From Baseline in FEV1 on Day 7
NCT01350128 (9) [back to overview]Peak Change From Baseline in IC on Day 1
NCT01415518 (24) [back to overview]Pre-dose FVC
NCT01415518 (24) [back to overview]Pre-dose FEV1
NCT01415518 (24) [back to overview]Post-dose PEF in Whole Treatment Period
NCT01415518 (24) [back to overview]Post-dose PEF in Last Week of Treatment
NCT01415518 (24) [back to overview]Post-dose PEF in First Week of Treatment
NCT01415518 (24) [back to overview]Post-dose IC at 60 Minutes
NCT01415518 (24) [back to overview]Post-dose FVC at 60 Minutes
NCT01415518 (24) [back to overview]Post-dose FVC at 5 Minutes
NCT01415518 (24) [back to overview]Pre-dose PEF in First Week of Treatment
NCT01415518 (24) [back to overview]Pre-dose IC
NCT01415518 (24) [back to overview]Pre-dose PEF in Last Week of Treatment
NCT01415518 (24) [back to overview]Pre-dose PEF in Whole Treatment Period
NCT01415518 (24) [back to overview]Use of Reliever Medication During Day in the First Week on Treatment
NCT01415518 (24) [back to overview]Use of Reliever Medication During Day in the Last Week on Treatment
NCT01415518 (24) [back to overview]Use of Reliever Medication During Day in the Whole Treatment Period
NCT01415518 (24) [back to overview]Use of Reliever Medication During Night in the First Week on Treatment
NCT01415518 (24) [back to overview]Post-dose FEV1 at 60 Minutes
NCT01415518 (24) [back to overview]Use of Reliever Medication During Night in the Last Week on Treatment
NCT01415518 (24) [back to overview]COPD Symptoms Sputum
NCT01415518 (24) [back to overview]COPD Symptoms - Cough
NCT01415518 (24) [back to overview]COPD Exacerbations
NCT01415518 (24) [back to overview]Change in COPD Symptoms - Breathing
NCT01415518 (24) [back to overview]Use of Reliever Medication During Night in the Whole Treatment Period
NCT01415518 (24) [back to overview]Post-dose FEV1 at 5 Minutes
NCT01426009 (7) [back to overview]Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7)
NCT01426009 (7) [back to overview]Rescue Medication Use
NCT01426009 (7) [back to overview]Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1)
NCT01426009 (7) [back to overview]Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests
NCT01426009 (7) [back to overview]Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7
NCT01426009 (7) [back to overview]Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)
NCT01426009 (7) [back to overview]Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)
NCT01691482 (7) [back to overview]Percentage of Days for Which Participants Achieved a >=12% and 200 Milliliter (mL) Increase From Baseline in FEV1
NCT01691482 (7) [back to overview]Percentage of Days for Which Participants Achieved a Threshold Increase From Baseline in FEV1 of 100 mL, 200 mL, and 250 mL
NCT01691482 (7) [back to overview]The Maximal Bronchodilator Response for the First Administered Agent
NCT01691482 (7) [back to overview]Variability in Daily FEV1, Estimated by Coefficient of Variation
NCT01691482 (7) [back to overview]Variability in Daily FEV1, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum Values)
NCT01691482 (7) [back to overview]Variability in Daily IC, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum)
NCT01691482 (7) [back to overview]Variability in Daily Inspiratory Capacity (IC), Estimated by Coefficient of Variation
NCT01696214 (3) [back to overview]Asthma Control Test
NCT01696214 (3) [back to overview]Percent (%) Perdicted FEV1 Changes
NCT01696214 (3) [back to overview]The Asthma Symptom Utility Index (ASUI)
NCT01943552 (6) [back to overview]Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Arterial Oxygen Pressure (PaO2) Value
NCT01943552 (6) [back to overview]Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Oxygen Saturation
NCT01943552 (6) [back to overview]Change of Forced Expiratory Volume in 1 Second (FEV1) From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery
NCT01943552 (6) [back to overview]Main Post-operative Pulmonary Complications (Including Pneumonia, Atelectasis and Acute Respiratory Failure) Within Three Weeks After the Surgery
NCT01943552 (6) [back to overview]Change of Forced Vital Capacity (FVC) From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery
NCT01943552 (6) [back to overview]Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Arterial Carbon Dioxide Pressure (PaCO2) Value
NCT01987219 (4) [back to overview]Change in Forced Expiratory Volume (FEV) From Baseline
NCT01987219 (4) [back to overview]Change in Forced Expiratory Flow Between 25-75% (FEF25-75)
NCT01987219 (4) [back to overview]Change From Baseline of Forced Vital Capacity
NCT01987219 (4) [back to overview]Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline
NCT03064113 (7) [back to overview]Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo
NCT03064113 (7) [back to overview]Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo
NCT03064113 (7) [back to overview]Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline
NCT03064113 (7) [back to overview]Area Under the Forced Vital Capacity (FVC) vs. Time Curve
NCT03064113 (7) [back to overview]Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1
NCT03064113 (7) [back to overview]Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1
NCT03064113 (7) [back to overview]Forced Vital Capacity (FVC)
NCT03219866 (9) [back to overview]Change in Pulmonary Inspiratory Force (PIF) From Baseline at 90 Days - R -5 (High Resistance Inhalers)
NCT03219866 (9) [back to overview]Change in Pulmonary Inspiratory Force (PIF) From Baseline at 90 Days - R -2 (Low to Medium Resistance Inhalers)
NCT03219866 (9) [back to overview]Symptom Control Measured by The Modified Medical Research Council Dyspnea Scale (mMRC)
NCT03219866 (9) [back to overview]Unscheduled Clinic or ER Visits
NCT03219866 (9) [back to overview]Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ)
NCT03219866 (9) [back to overview]Number of Deaths
NCT03219866 (9) [back to overview]COPD and All-Cause Hospital Readmissions After 90 Days
NCT03219866 (9) [back to overview]COPD and All-Cause Hospital Readmissions After 30 Days
NCT03219866 (9) [back to overview]Symptom Control Measured by the COPD Assessment Test (CAT)

FEV1 at 1 Hour at Week 12

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.327
Combivent (Ipratropium/Albuterol)1.41

[back to top]

Physician Global Evaluation

The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). (NCT00359788)
Timeframe: Week 6

InterventionUnits on a scale (Least Squares Mean)
Tiotropium4.867
Combivent (Ipratropium/Albuterol)4.716

[back to top]

Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks

Average hourly FEV1 AUC0-6 minus baseline FEV1 (NCT00359788)
Timeframe: Baseline and 12 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.187
Combivent (Ipratropium/Albuterol)0.167

[back to top]

Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6

Average hourly FEV1 AUC0-6 minus baseline FEV1 (NCT00359788)
Timeframe: Baseline and week 6

InterventionLiters (Least Squares Mean)
Tiotropium0.207
Combivent (Ipratropium/Albuterol)0.153

[back to top]

Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1

Average hourly FEV1 AUC0-6 minus baseline FEV1 (NCT00359788)
Timeframe: Day 1 (after first dose)

InterventionLiters (Least Squares Mean)
Tiotropium0.132
Combivent (Ipratropium/Albuterol)0.211

[back to top]

Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks

Average hourly FVC AUC0-6 minus baseline FVC (NCT00359788)
Timeframe: Baseline and 12 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.443
Combivent (Ipratropium/Albuterol)0.432

[back to top]

Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks

Average hourly FVC AUC0-6 minus baseline FVC (NCT00359788)
Timeframe: Baseline and 6 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.464
Combivent (Ipratropium/Albuterol)0.425

[back to top]

Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1

Average hourly FVC AUC0-6 minus baseline FVC (NCT00359788)
Timeframe: Day 1

InterventionLiters (Least Squares Mean)
Tiotropium0.327
Combivent (Ipratropium/Albuterol)0.484

[back to top]

Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12

Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: Baseline and 12 weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.209
Combivent (Ipratropium/Albuterol)0.342

[back to top]

Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6

Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: Baseline and 6 weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.204
Combivent (Ipratropium/Albuterol)0.356

[back to top]

Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1

Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: Day 1

InterventionLiters (Least Squares Mean)
Tiotropium0.232
Combivent (Ipratropium/Albuterol)0.364

[back to top]

Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12

Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: Baseline and 12 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.418
Combivent (Ipratropium/Albuterol)0.703

[back to top]

Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6

Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: baseline and 6 Weeks (after first dose)

InterventionLiters (Least Squares Mean)
Tiotropium0.43
Combivent (Ipratropium/Albuterol)0.791

[back to top]

Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1

Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication (NCT00359788)
Timeframe: Day 1

InterventionLiters (Least Squares Mean)
Tiotropium0.542
Combivent (Ipratropium/Albuterol)0.824

[back to top]

Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks

Trough FEV1 is measured 10 minutes before drug administration (NCT00359788)
Timeframe: Baseline and 12 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.081
Combivent (Ipratropium/Albuterol)-0.025

[back to top]

Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks

Trough FEV1 is measured 10 minutes before drug administration (NCT00359788)
Timeframe: Baseline and 6 Weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.11
Combivent (Ipratropium/Albuterol)-0.036

[back to top]

Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks

Trough FVC is measured 10 minutes before drug administration (NCT00359788)
Timeframe: Baseline and 12 weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.225
Combivent (Ipratropium/Albuterol)0.051

[back to top]

Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks

Trough FVC is measured 10 minutes before drug administration (NCT00359788)
Timeframe: Baseline and 6 weeks

InterventionLiters (Least Squares Mean)
Tiotropium0.258
Combivent (Ipratropium/Albuterol)-0.02

[back to top]

Day Time Albuterol Use During Week 1

Puffs of rescue albuterol used during the day in week 1 (NCT00359788)
Timeframe: Week 1

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.175
Combivent (Ipratropium/Albuterol)1.217

[back to top]

Day Time Albuterol Use During Week 10

Puffs of rescue albuterol used during the day in week 10 (NCT00359788)
Timeframe: Week 10

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.351
Combivent (Ipratropium/Albuterol)1.394

[back to top]

Day Time Albuterol Use During Week 11

Puffs of rescue albuterol used during the day in week 11 (NCT00359788)
Timeframe: Week 11

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.352
Combivent (Ipratropium/Albuterol)1.445

[back to top]

Day Time Albuterol Use During Week 12

Puffs of rescue albuterol used during the day in week 12 (NCT00359788)
Timeframe: Week 12

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.361
Combivent (Ipratropium/Albuterol)1.409

[back to top]

Day Time Albuterol Use During Week 2

Puffs of rescue albuterol used during the day in week 2 (NCT00359788)
Timeframe: Week 2

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.24
Combivent (Ipratropium/Albuterol)1.309

[back to top]

Day Time Albuterol Use During Week 3

Puffs of rescue albuterol used during the day in week 3 (NCT00359788)
Timeframe: Week 3

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.337
Combivent (Ipratropium/Albuterol)1.41

[back to top]

Day Time Albuterol Use During Week 4

Puffs of rescue albuterol used during the day in week 4 (NCT00359788)
Timeframe: Week 4

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.287
Combivent (Ipratropium/Albuterol)1.399

[back to top]

Day Time Albuterol Use During Week 5

Puffs of rescue albuterol used during the day in week 5 (NCT00359788)
Timeframe: Week 5

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.275
Combivent (Ipratropium/Albuterol)1.345

[back to top]

Day Time Albuterol Use During Week 6

Puffs of rescue albuterol used during the day in week 6 (NCT00359788)
Timeframe: Week 6

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.259
Combivent (Ipratropium/Albuterol)1.405

[back to top]

Day Time Albuterol Use During Week 7

Puffs of rescue albuterol used during the day in week 7 (NCT00359788)
Timeframe: Week 7

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.313
Combivent (Ipratropium/Albuterol)1.398

[back to top]

Day Time Albuterol Use During Week 8

Puffs of rescue albuterol used during the day in week 8 (NCT00359788)
Timeframe: Week 8

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.301
Combivent (Ipratropium/Albuterol)1.471

[back to top]

Day Time Albuterol Use During Week 9

Puffs of rescue albuterol used during the day in week 9 (NCT00359788)
Timeframe: Week 9

InterventionPuffs per day (Least Squares Mean)
Tiotropium1.369
Combivent (Ipratropium/Albuterol)1.43

[back to top]

Evening PEFR at Week 1

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 1

InterventionLiters/minute (Least Squares Mean)
Tiotropium222.89
Combivent (Ipratropium/Albuterol)222.64

[back to top]

Evening PEFR at Week 10

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 10

InterventionLiters/minute (Least Squares Mean)
Tiotropium220.46
Combivent (Ipratropium/Albuterol)216.32

[back to top]

Evening PEFR at Week 11

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 11

InterventionLiters/minute (Least Squares Mean)
Tiotropium218.35
Combivent (Ipratropium/Albuterol)217.17

[back to top]

Evening PEFR at Week 12

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 12

InterventionLiters/minute (Least Squares Mean)
Tiotropium219.66
Combivent (Ipratropium/Albuterol)215.46

[back to top]

Evening PEFR at Week 2

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 2

InterventionLiters/minute (Least Squares Mean)
Tiotropium221.97
Combivent (Ipratropium/Albuterol)221.12

[back to top]

Evening PEFR at Week 3

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 3

InterventionLiters/minute (Least Squares Mean)
Tiotropium221.23
Combivent (Ipratropium/Albuterol)218.52

[back to top]

Evening PEFR at Week 4

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 4

InterventionLiters/minute (Least Squares Mean)
Tiotropium221.96
Combivent (Ipratropium/Albuterol)215.06

[back to top]

Evening PEFR at Week 5

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 5

InterventionLiters/minute (Least Squares Mean)
Tiotropium217.95
Combivent (Ipratropium/Albuterol)214.53

[back to top]

Evening PEFR at Week 6

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 6

InterventionLiters/minute (Least Squares Mean)
Tiotropium218.45
Combivent (Ipratropium/Albuterol)219.42

[back to top]

Evening PEFR at Week 7

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 7

InterventionLiters/minute (Least Squares Mean)
Tiotropium220.98
Combivent (Ipratropium/Albuterol)220.79

[back to top]

Evening PEFR at Week 8

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 8

InterventionLiters/minute (Least Squares Mean)
Tiotropium223.33
Combivent (Ipratropium/Albuterol)218.2

[back to top]

Evening PEFR at Week 9

Weekly means for evening PEFR (NCT00359788)
Timeframe: Week 9

InterventionLiters/minute (Least Squares Mean)
Tiotropium221.47
Combivent (Ipratropium/Albuterol)217.41

[back to top]

FEV1 at -10 Minutes at Week 12

(NCT00359788)
Timeframe: 10 minutes before dosing

InterventionLiters (Least Squares Mean)
Tiotropium1.225
Combivent (Ipratropium/Albuterol)1.119

[back to top]

FEV1 at -10 Minutes at Week 6

(NCT00359788)
Timeframe: 10 minutes before dosing

InterventionLiters (Least Squares Mean)
Tiotropium1.254
Combivent (Ipratropium/Albuterol)1.108

[back to top]

Morning Peak Expiratory Flow Rate (PEFR) at Week 1

(NCT00359788)
Timeframe: Week 1

InterventionLiters/minute (Least Squares Mean)
Tiotropium205.8
Combivent (Ipratropium/Albuterol)195.1

[back to top]

FEV1 at 1 Hour at Week 6

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.343
Combivent (Ipratropium/Albuterol)1.405

[back to top]

FEV1 at 1 Hour on Day 1

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.272
Combivent (Ipratropium/Albuterol)1.455

[back to top]

FEV1 at 15 Minutes at Week 12

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.268
Combivent (Ipratropium/Albuterol)1.351

[back to top]

FEV1 at 15 Minutes at Week 6

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.3
Combivent (Ipratropium/Albuterol)1.355

[back to top]

FEV1 at 15 Minutes on Day 1

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.214
Combivent (Ipratropium/Albuterol)1.389

[back to top]

FEV1 at 2 Hours at Week 12

(NCT00359788)
Timeframe: 2 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.353
Combivent (Ipratropium/Albuterol)1.398

[back to top]

FEV1 at 2 Hours at Week 6

(NCT00359788)
Timeframe: 2 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.364
Combivent (Ipratropium/Albuterol)1.382

[back to top]

FEV1 at 2 Hours on Day 1

(NCT00359788)
Timeframe: 2 hour

InterventionLeast Squares Mean (Least Squares Mean)
Tiotropium1.293
Combivent (Ipratropium/Albuterol)1.43

[back to top]

FEV1 at 3 Hours at Week 12

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.353
Combivent (Ipratropium/Albuterol)1.333

[back to top]

FEV1 at 3 Hours at Week 6

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.371
Combivent (Ipratropium/Albuterol)1.31

[back to top]

FEV1 at 3 Hours on Day 1

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.29
Combivent (Ipratropium/Albuterol)1.375

[back to top]

FEV1 at 30 Minutes at Week 12

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.306
Combivent (Ipratropium/Albuterol)1.393

[back to top]

FEV1 at 30 Minutes at Week 6

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.328
Combivent (Ipratropium/Albuterol)1.388

[back to top]

FEV1 at 30 Minutes on Day 1

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium1.261
Combivent (Ipratropium/Albuterol)1.429

[back to top]

FEV1 at 4 Hours at Week 12

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.337
Combivent (Ipratropium/Albuterol)1.263

[back to top]

FEV1 at 4 Hours at Week 6

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.369
Combivent (Ipratropium/Albuterol)1.247

[back to top]

FEV1 at 4 Hours on Day 1

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.284
Combivent (Ipratropium/Albuterol)1.319

[back to top]

FEV1 at 6 Hours at Week 12

(NCT00359788)
Timeframe: 6 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.318
Combivent (Ipratropium/Albuterol)1.182

[back to top]

FEV1 at 6 Hours at Week 6

(NCT00359788)
Timeframe: 6 hour

InterventionLiters (Least Squares Mean)
Tiotropium1.33
Combivent (Ipratropium/Albuterol)1.168

[back to top]

FEV1 at 6 Hours on Day 1

(NCT00359788)
Timeframe: 6 hours

InterventionLiters (Least Squares Mean)
Tiotropium1.269
Combivent (Ipratropium/Albuterol)1.233

[back to top]

FVC at -10 Minutes at Week 12

(NCT00359788)
Timeframe: 10 minutes before dosing

InterventionLiters (Least Squares Mean)
Tiotropium2.967
Combivent (Ipratropium/Albuterol)2.792

[back to top]

FVC at -10 Minutes at Week 6

(NCT00359788)
Timeframe: 10 minutes before dosing

InterventionLiters (Least Squares Mean)
Tiotropium3
Combivent (Ipratropium/Albuterol)2.722

[back to top]

FVC at 1 Hour at Week 12

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.177
Combivent (Ipratropium/Albuterol)3.375

[back to top]

FVC at 1 Hour at Week 6

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.206
Combivent (Ipratropium/Albuterol)3.388

[back to top]

FVC at 1 Hour on Day 1

(NCT00359788)
Timeframe: 1 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.087
Combivent (Ipratropium/Albuterol)3.444

[back to top]

FVC at 15 Minutes at Week 12

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium3.069
Combivent (Ipratropium/Albuterol)3.263

[back to top]

FVC at 15 Minutes at Week 6

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium3.09
Combivent (Ipratropium/Albuterol)3.279

[back to top]

FVC at 15 Minutes on Day 1

(NCT00359788)
Timeframe: 15 minutes

InterventionLiters (Least Squares Mean)
Tiotropium2.938
Combivent (Ipratropium/Albuterol)3.308

[back to top]

FVC at 2 Hours at Week 12

(NCT00359788)
Timeframe: 2 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.231
Combivent (Ipratropium/Albuterol)3.328

[back to top]

FVC at 2 Hours at Week 6

(NCT00359788)
Timeframe: 2 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.227
Combivent (Ipratropium/Albuterol)3.338

[back to top]

FVC at 2 Hours on Day 1

(NCT00359788)
Timeframe: 2 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.103
Combivent (Ipratropium/Albuterol)3.388

[back to top]

FVC at 3 Hours at Week 12

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.226
Combivent (Ipratropium/Albuterol)3.218

[back to top]

FVC at 3 Hours at Week 6

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.235
Combivent (Ipratropium/Albuterol)3.185

[back to top]

FVC at 3 Hours on Day 1

(NCT00359788)
Timeframe: 3 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.091
Combivent (Ipratropium/Albuterol)3.261

[back to top]

FVC at 30 Minutes at Week 12

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium3.143
Combivent (Ipratropium/Albuterol)3.358

[back to top]

FVC at 30 Minutes at Week 6

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium3.158
Combivent (Ipratropium/Albuterol)3.362

[back to top]

FVC at 30 Minutes on Day 1

(NCT00359788)
Timeframe: 30 minutes

InterventionLiters (Least Squares Mean)
Tiotropium3.044
Combivent (Ipratropium/Albuterol)3.4

[back to top]

FVC at 4 Hours at Week 12

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.199
Combivent (Ipratropium/Albuterol)3.074

[back to top]

FVC at 4 Hours at Week 6

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.23
Combivent (Ipratropium/Albuterol)3.068

[back to top]

FVC at 4 Hours on Day 1

(NCT00359788)
Timeframe: 4 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.087
Combivent (Ipratropium/Albuterol)3.136

[back to top]

FVC at 6 Hours at Week 12

(NCT00359788)
Timeframe: 6 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.155
Combivent (Ipratropium/Albuterol)2.932

[back to top]

FVC at 6 Hours at Week 6

(NCT00359788)
Timeframe: 6 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.190
Combivent (Ipratropium/Albuterol)2.914

[back to top]

FVC at 6 Hours on Day 1

(NCT00359788)
Timeframe: 6 hour

InterventionLiters (Least Squares Mean)
Tiotropium3.053
Combivent (Ipratropium/Albuterol)2.972

[back to top]

Morning PEFR at Week 10

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 10

InterventionLiters/minute (Least Squares Mean)
Tiotropium204.83
Combivent (Ipratropium/Albuterol)193.23

[back to top]

Morning PEFR at Week 11

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 11

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.47
Combivent (Ipratropium/Albuterol)195.47

[back to top]

Morning PEFR at Week 12

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 12

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.52
Combivent (Ipratropium/Albuterol)192.44

[back to top]

Morning PEFR at Week 2

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 2

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.07
Combivent (Ipratropium/Albuterol)194.81

[back to top]

Morning PEFR at Week 3

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 3

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.61
Combivent (Ipratropium/Albuterol)193.83

[back to top]

Morning PEFR at Week 4

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 4

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.76
Combivent (Ipratropium/Albuterol)193.19

[back to top]

Morning PEFR at Week 5

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 5

InterventionLiters/minute (Least Squares Mean)
Tiotropium205.6
Combivent (Ipratropium/Albuterol)193.55

[back to top]

Morning PEFR at Week 6

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 6

InterventionLiters/minute (Least Squares Mean)
Tiotropium206.49
Combivent (Ipratropium/Albuterol)195.38

[back to top]

Morning PEFR at Week 7

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 7

InterventionLiters/minute (Least Squares Mean)
Tiotropium208.72
Combivent (Ipratropium/Albuterol)197.66

[back to top]

Morning PEFR at Week 8

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 8

InterventionLiters/minute (Least Squares Mean)
Tiotropium208.88
Combivent (Ipratropium/Albuterol)195.22

[back to top]

Morning PEFR at Week 9

Weekly means for morning PEFR (NCT00359788)
Timeframe: Week 9

InterventionLiters/minute (Least Squares Mean)
Tiotropium208.97
Combivent (Ipratropium/Albuterol)194.74

[back to top]

Night Time Albuterol Use During Week 1

(NCT00359788)
Timeframe: Week 1

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.493
Combivent (Ipratropium/Albuterol)2.966

[back to top]

Night Time Albuterol Use During Week 10

Puffs of rescue albuterol used during the night in week 10 (NCT00359788)
Timeframe: Week 10

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.199
Combivent (Ipratropium/Albuterol)2.909

[back to top]

Night Time Albuterol Use During Week 11

Puffs of rescue albuterol used during the night in week 11 (NCT00359788)
Timeframe: Week 11

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.224
Combivent (Ipratropium/Albuterol)2.907

[back to top]

Night Time Albuterol Use During Week 12

Puffs of rescue albuterol used during the night in week 12 (NCT00359788)
Timeframe: Week 12

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.178
Combivent (Ipratropium/Albuterol)3.069

[back to top]

Night Time Albuterol Use During Week 2

Puffs of rescue albuterol used during the night in week 2 (NCT00359788)
Timeframe: Week 2

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.269
Combivent (Ipratropium/Albuterol)3.004

[back to top]

Night Time Albuterol Use During Week 3

Puffs of rescue albuterol used during the night in week 3 (NCT00359788)
Timeframe: Week 3

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.282
Combivent (Ipratropium/Albuterol)2.931

[back to top]

Night Time Albuterol Use During Week 4

Puffs of rescue albuterol used during the night in week 4 (NCT00359788)
Timeframe: Week 4

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.285
Combivent (Ipratropium/Albuterol)2.921

[back to top]

Night Time Albuterol Use During Week 5

Puffs of rescue albuterol used during the night in week 5 (NCT00359788)
Timeframe: Week 5

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.152
Combivent (Ipratropium/Albuterol)2.789

[back to top]

Night Time Albuterol Use During Week 6

Puffs of rescue albuterol used during the night in week 6 (NCT00359788)
Timeframe: Week 6

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.178
Combivent (Ipratropium/Albuterol)2.806

[back to top]

Night Time Albuterol Use During Week 7

Puffs of rescue albuterol used during the night in week 7 (NCT00359788)
Timeframe: Week 7

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.156
Combivent (Ipratropium/Albuterol)2.966

[back to top]

Night Time Albuterol Use During Week 8

Puffs of rescue albuterol used during the night in week 8 (NCT00359788)
Timeframe: Week 8

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.104
Combivent (Ipratropium/Albuterol)2.983

[back to top]

Night Time Albuterol Use During Week 9

Puffs of rescue albuterol used during the night in week 9 (NCT00359788)
Timeframe: Week 9

InterventionPuffs per night (Least Squares Mean)
Tiotropium3.254
Combivent (Ipratropium/Albuterol)3.006

[back to top]

Patient Global Evaluation

The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to chronic obstructive pulmonary disease (COPD). The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8) (NCT00359788)
Timeframe: Week 6

InterventionUnits on a scale (Least Squares Mean)
Tiotropium4.273
Combivent (Ipratropium/Albuterol)4.069

[back to top]

Patient Global Evaluation

The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). (NCT00359788)
Timeframe: Week 12

InterventionUnits on a scale (Least Squares Mean)
Tiotropium4.49
Combivent (Ipratropium/Albuterol)4.239

[back to top]

Physician Global Evaluation

The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). (NCT00359788)
Timeframe: Week 12

InterventionUnits on a scale (Least Squares Mean)
Tiotropium5.057
Combivent (Ipratropium/Albuterol)4.772

[back to top]

Mean Change in Asthma Score at 2 Hours

The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator

InterventionUnits on a scale (Mean)
Budesonide Inhalation Suspension (BIS)-2.9
Placebo (Normal Saline)-3.0

[back to top]

Change in Mean Heart Rate

Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol (NCT00393367)
Timeframe: From the initial heart rate to heart rate 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionBeats per minute (Mean)
Budesonide Inhalation Suspension (BIS)12
Placebo (Normal Saline)13

[back to top]

Mean Change in Respiratory Rate.

Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator. (NCT00393367)
Timeframe: Initial rate, minus rate taken 2 hours after budesonide/albuterol intervention or saline/albuterol comparator

InterventionBreaths per minute (Mean)
Budesonide Inhalation Suspension (BIS)-6
Placebo (Normal Saline)-6

[back to top]

Median Change in Asthma Score 2 Hours After Intervention

The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator

InterventionUnits on a scale (Median)
Budesonide Inhalation Suspension (BIS)-3
Placebo (Normal Saline)-3

[back to top]

Number of Patients Hospitalized

The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician. (NCT00393367)
Timeframe: within 4 hours after the budesonide/albuterol intervention or saline/albuterol placebo

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)56
Placebo (Saline)55

[back to top]

Number of Subjects Moving From the Severe Asthma to Mild Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)8
Placebo (Normal Saline)10

[back to top]

Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)22
Placebo (Normal Saline)11

[back to top]

Number of Subjects Remaining in the Severe Asthma Category

Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)4
Placebo (Normal Saline)4

[back to top]

Oxygen Saturation.

Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment. (NCT00393367)
Timeframe: 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator

InterventionPercent Hemoglobin Saturation (Mean)
Budesonide Inhalation Suspension (BIS)1.0
Placebo (Normal Saline)1.0

[back to top]

Relapse / Readmission Numbers.

Participants admitted to the hospital within 5 days of the ED visit (NCT00393367)
Timeframe: within 5 days of ED visit

InterventionParticipants (Number)
Budesonide Inhalation Suspension (BIS)2
Placebo (Normal Saline)2

[back to top]

Number of Participants With Adverse Events (Non-serious).

(NCT00393367)
Timeframe: within 30 days of the ED visit

,
InterventionParticipants (Number)
RhinorrheaHeadacheDiarrheaSore throatCoughHyperglycemia
Budesonide Inhalation Suspension (BIS)653422
Placebo (Normal Saline)1197330

[back to top]

Serious Adverse Events

Serious Adverse Events (NCT00393367)
Timeframe: 0-5 days

,
Interventionparticipants (Number)
Return within 5 days with hosptial admissionIncreased level of care
Budesonide Inhalation Suspension (BIS)21
Placebo (Saline)20

[back to top]

Duration of Therapeutic FEV1 Response at Day 57

The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 57 (NCT00400153)
Timeframe: During the 6-hour observation period after drug administration at Day 57

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg165
COMBIVENT CFC-MDI 36/206 mcg194
Ipratropium Respimat 20 mcg84

[back to top]

Duration of Therapeutic FEV1 Response at Day 85

The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 85 (NCT00400153)
Timeframe: During the 6-hour observation period after drug administration at Day 85

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg168
COMBIVENT CFC-MDI 36/206 mcg172
Ipratropium Respimat 20 mcg70

[back to top]

FEV1 AUC0-4 at Day 1

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.211
COMBIVENT CFC-MDI 36/206 mcg0.227
Ipratropium Respimat 20 mcg0.149

[back to top]

FEV1 AUC0-4 at Day 29

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.197
COMBIVENT CFC-MDI 36/206 mcg0.198
Ipratropium Respimat 20 mcg0.153

[back to top]

FEV1 AUC0-4 at Day 57

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.188
COMBIVENT CFC-MDI 36/206 mcg0.200
Ipratropium Respimat 20 mcg0.141

[back to top]

FEV1 AUC0-4 at Day 85

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.189
COMBIVENT CFC-MDI 36/206 mcg0.190
Ipratropium Respimat 20 mcg0.142

[back to top]

FEV1 AUC0-6 at Day 1

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.173
COMBIVENT CFC-MDI 36/206 mcg0.189
Ipratropium Respimat 20 mcg0.124

[back to top]

FEV1 AUC0-6 at Day 29

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.154
COMBIVENT CFC-MDI 36/206 mcg0.161
Ipratropium Respimat 20 mcg0.127

[back to top]

FEV1 AUC0-6 at Day 57

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.146
COMBIVENT CFC-MDI 36/206 mcg0.16
Ipratropium Respimat 20 mcg0.118

[back to top]

FEV1 AUC0-6 at Day 85

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.145
COMBIVENT CFC-MDI 36/206 mcg0.149
Ipratropium Respimat 20 mcg0.119

[back to top]

FEV1 AUC4-6 at Day 1

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.1
COMBIVENT CFC-MDI 36/206 mcg0.115
Ipratropium Respimat 20 mcg0.074

[back to top]

FEV1 AUC4-6 at Day 29

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.068
COMBIVENT CFC-MDI 36/206 mcg0.087
Ipratropium Respimat 20 mcg0.078

[back to top]

FEV1 AUC4-6 at Day 57

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.063
COMBIVENT CFC-MDI 36/206 mcg0.084
Ipratropium Respimat 20 mcg0.073

[back to top]

FEV1 AUC4-6 at Day 85

Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.056
COMBIVENT CFC-MDI 36/206 mcg0.066
Ipratropium Respimat 20 mcg0.073

[back to top]

FVC AUC0-4 at Day 1

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.408
COMBIVENT CFC-MDI 36/206 mcg0.422
Ipratropium Respimat 20 mcg0.297

[back to top]

FVC AUC0-4 at Day 29

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.381
COMBIVENT CFC-MDI 36/206 mcg0.388
Ipratropium Respimat 20 mcg0.291

[back to top]

FVC AUC0-4 at Day 57

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.361
COMBIVENT CFC-MDI 36/206 mcg0.380
Ipratropium Respimat 20 mcg0.264

[back to top]

FVC AUC0-4 at Day 85

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85 (NCT00400153)
Timeframe: Before drug administration to 4 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.359
COMBIVENT CFC-MDI 36/206 mcg0.359
Ipratropium Respimat 20 mcg0.265

[back to top]

FVC AUC0-6 at Day 1

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration at Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.337
COMBIVENT CFC-MDI 36/206 mcg0.354
Ipratropium Respimat 20 mcg0.25

[back to top]

FVC AUC0-6 at Day 29

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration at Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.3
COMBIVENT CFC-MDI 36/206 mcg0.319
Ipratropium Respimat 20 mcg0.246

[back to top]

FVC AUC0-6 at Day 57

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.284
COMBIVENT CFC-MDI 36/206 mcg0.303
Ipratropium Respimat 20 mcg0.22

[back to top]

FVC AUC0-6 at Day 85

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85 (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.279
COMBIVENT CFC-MDI 36/206 mcg0.283
Ipratropium Respimat 20 mcg0.219

[back to top]

FVC AUC4-6 at Day 1

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.2
COMBIVENT CFC-MDI 36/206 mcg0.221
Ipratropium Respimat 20 mcg0.156

[back to top]

FVC AUC4-6 at Day 29

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.137
COMBIVENT CFC-MDI 36/206 mcg0.180
Ipratropium Respimat 20 mcg0.156

[back to top]

FVC AUC4-6 at Day 57

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.128
COMBIVENT CFC-MDI 36/206 mcg0.147
Ipratropium Respimat 20 mcg0.13

[back to top]

FVC AUC4-6 at Day 85

Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85 (NCT00400153)
Timeframe: Between 4 hours and 6 hours after drug administration on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.117
COMBIVENT CFC-MDI 36/206 mcg0.130
Ipratropium Respimat 20 mcg0.124

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.729
RESPIMAT Device6.150

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.326
RESPIMAT Device5.808

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device6.048
RESPIMAT Device6.275

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.411
RESPIMAT Device5.810

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.639
RESPIMAT Device6.103

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.715
RESPIMAT Device6.117

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device4.573
RESPIMAT Device6.184

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device6.014
RESPIMAT Device6.279

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.682
RESPIMAT Device6.190

[back to top]

Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler

"Patients rated their response on a seven point Likert scale:~1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied." (NCT00400153)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
MDI Device5.749
RESPIMAT Device6.127

[back to top]

Night-time Rescue Medication Use

The mean number of puffs of rescue medication used during the night-time per week during the entire study (including baseline and on-treatment period) (NCT00400153)
Timeframe: During the 2-week baseline washout period and the 12-week treatment period

Interventionpuffs (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.977
COMBIVENT CFC-MDI 36/206 mcg0.977
Ipratropium Respimat 20 mcg0.997

[back to top]

Night-time Symptom Score

"The weekly mean night-time symptom score per week during the entire study (including baseline and on-treatment period).~Night-time COPD symptoms: 0=none 1=some - slept well 2=woke once 3=woke several times 4=woke most of night" (NCT00400153)
Timeframe: During the 2-week baseline washout period and the 12-week treatment period

Interventionunits on a scale (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.922
COMBIVENT CFC-MDI 36/206 mcg0.914
Ipratropium Respimat 20 mcg0.857

[back to top]

Noncompartmental Parameters of Albuterol at Steady State

Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose). (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 29

Interventionng*h/mL (Geometric Mean)
COMBIVENT Respimat 20/100 mcg4.09
COMBIVENT CFC-MDI 36/206 mcg5.52

[back to top]

Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State

Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCτ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose). (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 29

Interventionpg*h/mL (Geometric Mean)
COMBIVENT Respimat 20/100 mcg128
COMBIVENT CFC-MDI 36/206 mcg123
Ipratropium Respimat 20 mcg115

[back to top]

Peak FEV1 Response at Day 1

Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval on Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.302
COMBIVENT CFC-MDI 36/206 mcg0.323
Ipratropium Respimat 20 mcg0.237

[back to top]

Peak FEV1 Response at Day 29

Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval on Day 29

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.302
Ipratropium Respimat 20 mcg0.237
COMBIVENT CFC-MDI 36/206 mcg0.296

[back to top]

Peak FEV1 Response at Day 57

Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval on Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.284
COMBIVENT CFC-MDI 36/206 mcg0.296
Ipratropium Respimat 20 mcg0.223

[back to top]

Peak FEV1 Response at Day 85

Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval on Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.293
COMBIVENT CFC-MDI 36/206 mcg0.290
Ipratropium Respimat 20 mcg0.225

[back to top]

Peak FVC Response at Day 1

Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 1

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.6
COMBIVENT CFC-MDI 36/206 mcg0.612
Ipratropium Respimat 20 mcg0.479

[back to top]

Peak FVC Response at Day 29

Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 29

Interventionliters (Least Squares Mean)
COMBIVENT CFC-MDI 36/206 mcg0.591
Ipratropium Respimat 20 mcg0.465
COMBIVENT Respimat 20/100 mcg0.594

[back to top]

Peak FVC Response at Day 57

Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 57

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.562
COMBIVENT CFC-MDI 36/206 mcg0.577
Ipratropium Respimat 20 mcg0.445

[back to top]

Peak FVC Response at Day 85

Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 85

Interventionliters (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg0.575
COMBIVENT CFC-MDI 36/206 mcg0.562
Ipratropium Respimat 20 mcg0.449

[back to top]

Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period

COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission. (NCT00400153)
Timeframe: During the 12-week on-treatment period

InterventionPercentage of patients (Number)
COMBIVENT Respimat 20/100 mcg14.81
COMBIVENT CFC-MDI 36/206 mcg13.03
Ipratropium Respimat 20 mcg10.35

[back to top]

Physician's Global Evaluation Score on Pulmonary Function Testing Day 29

"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.~Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent." (NCT00400153)
Timeframe: Prior to pulmonary function test on Day 29

Interventionunits on a scale (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg4.936
COMBIVENT CFC-MDI 36/206 mcg4.859
Ipratropium Respimat 20 mcg4.99

[back to top]

Physician's Global Evaluation Score on Pulmonary Function Testing Day 57

"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.~Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent." (NCT00400153)
Timeframe: Prior to pulmonary function test on Day 57

Interventionunits on a scale (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg4.971
COMBIVENT CFC-MDI 36/206 mcg4.965
Ipratropium Respimat 20 mcg5.04

[back to top]

Physician's Global Evaluation Score on Pulmonary Function Testing Day 85

"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.~Score: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent." (NCT00400153)
Timeframe: Prior to pulmonary function test on Day 85

Interventionunits on a scale (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg5.115
COMBIVENT CFC-MDI 36/206 mcg5.018
Ipratropium Respimat 20 mcg5.097

[back to top]

Rescue Medication Use on Pulmonary Test Day 1

Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 1 (NCT00400153)
Timeframe: During the 6-hour pulmonary function testing after drug administration on Day 1

Interventionpatients (Number)
COMBIVENT Respimat 20/100 mcg8
COMBIVENT CFC-MDI 36/206 mcg9
Ipratropium Respimat 20 mcg7

[back to top]

Rescue Medication Use on Pulmonary Test Day 29

Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 29 (NCT00400153)
Timeframe: During the 6-hour pulmonary function testing after drug administration on Day 29

Interventionpatients (Number)
COMBIVENT Respimat 20/100 mcg10
COMBIVENT CFC-MDI 36/206 mcg7
Ipratropium Respimat 20 mcg7

[back to top]

Rescue Medication Use on Pulmonary Test Day 57

Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 57 (NCT00400153)
Timeframe: During the 6-hour pulmonary function testing after drug administration on Day 57

Interventionpatients (Number)
COMBIVENT Respimat 20/100 mcg7
COMBIVENT CFC-MDI 36/206 mcg7
Ipratropium Respimat 20 mcg6

[back to top]

Rescue Medication Use on Pulmonary Test Day 85

Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 85 (NCT00400153)
Timeframe: During the 6-hour pulmonary function testing after drug administration on Day 85

Interventionpatients (Number)
COMBIVENT Respimat 20/100 mcg5
COMBIVENT CFC-MDI 36/206 mcg7
Ipratropium Respimat 20 mcg10

[back to top]

Time to Onset of Therapeutic FEV1 Response at Day 1

Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 1 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 1

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg13
COMBIVENT CFC-MDI 36/206 mcg12
Ipratropium Respimat 20 mcg28

[back to top]

Time to Onset of Therapeutic FEV1 Response at Day 29

Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 29 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 29

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg12
COMBIVENT CFC-MDI 36/206 mcg13
Ipratropium Respimat 20 mcg27

[back to top]

Time to Onset of Therapeutic FEV1 Response at Day 57

Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 57 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 57

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg13
COMBIVENT CFC-MDI 36/206 mcg12
Ipratropium Respimat 20 mcg29

[back to top]

Time to Onset of Therapeutic FEV1 Response at Day 85

Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 85 (NCT00400153)
Timeframe: Within the first 2-hour post-treatment interval at Day 85

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg12
COMBIVENT CFC-MDI 36/206 mcg13
Ipratropium Respimat 20 mcg27

[back to top]

Time to Peak FEV1 Response at Day 1

The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 1 (NCT00400153)
Timeframe: Within the 6-hour post-treatment observation period at Day 1

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg60
COMBIVENT CFC-MDI 36/206 mcg60
Ipratropium Respimat 20 mcg120

[back to top]

Time to Peak FEV1 Response at Day 29

The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 29 (NCT00400153)
Timeframe: Within the 6-hour post-treatment observation period at Day 29

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg60
COMBIVENT CFC-MDI 36/206 mcg60
Ipratropium Respimat 20 mcg120

[back to top]

Time to Peak FEV1 Response at Day 57

The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 57 (NCT00400153)
Timeframe: Within the 6-hour post-treatment observation period at Day 57

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg60
COMBIVENT CFC-MDI 36/206 mcg60
Ipratropium Respimat 20 mcg60

[back to top]

Time to Peak FEV1 Response at Day 85

The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 85 (NCT00400153)
Timeframe: Within the 6-hour post-treatment observation period at Day 85

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg60
COMBIVENT CFC-MDI 36/206 mcg60
Ipratropium Respimat 20 mcg60

[back to top]

Trough Peak Expiratory Flow Rate (PEFR)

The weekly mean trough PEFR during the entire study (including baseline and on-treatment period) (NCT00400153)
Timeframe: During the 2-week baseline washout period and the 12-week treatment period and PEFR taken before administration of study medication

Interventionliters/min (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg191.95
COMBIVENT CFC-MDI 36/206 mcg190.290
Ipratropium Respimat 20 mcg189.51

[back to top]

Device Preference (Respimat or MDI)

Frequency of patients due to device preference (NCT00400153)
Timeframe: 12 weeks

Interventionparticipants (Number)
Prefer RespimatPrefer MDINo preference
Number of Patients584146105

[back to top]

Frequency Distribution of Satisfaction Rating With Inhaler Attributes

(NCT00400153)
Timeframe: 12 weeks

,
Interventionparticipants (Number)
Very dissatisfiedDissatisfiedSomewhat dissatisfiedSatisfied/dissatisfiedSomewhat satisfiedSatisfiedVery satisfied
MDI Device16273754109351240
RESPIMAT Device1320172746305407

[back to top]

Rating of Action of Turning Clear Base of Respimat

Frequency of patients due to rating of action of turning clear base of Respimat (NCT00400153)
Timeframe: 12 weeks

Interventionparticipants (Number)
Very easyEasyNeither easy nor difficultDifficultVery difficult
Number of Patients5872044040

[back to top]

COPD Exacerbation During the On-treatment Period

COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission. (NCT00400153)
Timeframe: During the 12-week on-treatment period

InterventionPercentage of patients (Number)
COMBIVENT Respimat 20/100 mcg3.27
COMBIVENT CFC-MDI 36/206 mcg2.93
Ipratropium Respimat 20 mcg2.13

[back to top]

COPD Exacerbation Rate During the On-treatment Period

Proportion of patients experiencing a COPD exacerbation per patient year. COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission. (NCT00400153)
Timeframe: During the 12-week on-treatment period

InterventionProportion of patients (Number)
COMBIVENT Respimat 20/100 mcg0.76
COMBIVENT CFC-MDI 36/206 mcg0.69
Ipratropium Respimat 20 mcg0.53

[back to top]

Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-2 Hours

Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0-2,ss. (NCT00400153)
Timeframe: Before drug administration to 2 hours after drug administration on Day 29

Interventionμg (Geometric Mean)
COMBIVENT Respimat 20/100 mcg14.7
COMBIVENT CFC-MDI 36/206 mcg20.3

[back to top]

Cumulative Amounts of Albuterol [μg] Excreted in Urine for 0-6 Hours

Cumulative amounts of Albuterol [μg] excreted in urine - Planned time intervals 0-6, ss (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 29

Interventionμg (Geometric Mean)
COMBIVENT Respimat 20/100 mcg33.7
COMBIVENT CFC-MDI 36/206 mcg39.4

[back to top]

Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-2 Hours

Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0-2, ss (NCT00400153)
Timeframe: Before drug administration to 2 hours after drug administration on Day 29

Interventionμg (Geometric Mean)
COMBIVENT Respimat 20/100 mcg0.747
COMBIVENT CFC-MDI 36/206 mcg0.692
Ipratropium Respimat 20 Mcg0.723

[back to top]

Cumulative Amounts of Ipratropium [μg] Excreted in Urine for 0-6 Hours

Cumulative amounts of Ipratropium [μg] excreted in urine - Planned time intervals 0-6,ss (NCT00400153)
Timeframe: Before drug administration to 6 hours after drug administration on Day 26

Interventionμg (Geometric Mean)
COMBIVENT Respimat 20/100 mcg1.66
COMBIVENT CFC-MDI 36/206 mcg1.41
Ipratropium Respimat 20 mcg1.51

[back to top]

Daytime Rescue Medication Use

The mean number of puffs of rescue medication used during the daytime per week during the entire study (including baseline and on-treatment period) (NCT00400153)
Timeframe: During the 2-week baseline washout period and the 12-week treatment period

Interventionpuffs (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg2.3
COMBIVENT CFC-MDI 36/206 mcg2.191
Ipratropium Respimat 20 mcg2.456

[back to top]

Daytime Symptom Score

"The weekly mean daytime symptom score per week during the entire study (including baseline and on-treatment period).~Daytime COPD symptoms: 0=none 1=occasional 2=frequent, no interference with activities 3=most of day, interference with activities 4=prevent working and activities" (NCT00400153)
Timeframe: During the 2-week baseline washout period and the 12-week treatment period

Interventionunits on a scale (Least Squares Mean)
COMBIVENT Respimat 20/100 mcg1.015
COMBIVENT CFC-MDI 36/206 mcg1.002
Ipratropium Respimat 20 mcg0.999

[back to top]

Duration of Therapeutic FEV1 Response at Day 1

The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 1 (NCT00400153)
Timeframe: During the 6-hour observation period after drug administration at Day 1

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg189
COMBIVENT CFC-MDI 36/206 mcg219
Ipratropium Respimat 20 mcg104

[back to top]

Duration of Therapeutic FEV1 Response at Day 29

The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 29 (NCT00400153)
Timeframe: During the 6-hour observation period after drug administration at Day 29

InterventionMinutes (Median)
COMBIVENT Respimat 20/100 mcg170
COMBIVENT CFC-MDI 36/206 mcg178
Ipratropium Respimat 20 mcg122

[back to top]

Mean Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Final Evaluation

Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Forced Expiratory Volume in 1 second. FEV1 is defined as the volume of air that can be forced out of the lungs in 1 second after taking a deep breath. (NCT00460577)
Timeframe: Baseline,4 hours

InterventionLiters (Mean)
Formoterol (Foradil®)0.32
Fenoterol 0.5 mg + Berodual®0.34

[back to top]

Mean Change in Maximum Expiratory Flow From Baseline to Final Evaluation

Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Maximum Expiratory Flow. (NCT00460577)
Timeframe: Baseline,4 hours

InterventionLiters/minute (Mean)
Formoterol (Foradil®)44
Fenoterol 0.5 mg + Berodual®43.67

[back to top]

Mean Change in Pulse Oxymetry From Baseline to Final Evaluation

Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by Pulse Oximetry used to monitor the percentage of oxygen saturation of hemoglobin in the blood. (NCT00460577)
Timeframe: Baseline, 4 hours

Interventionpercentage (Mean)
Formoterol (Foradil®)2.57
Fenoterol 0.5 mg + Berodual®2.83

[back to top]

Mean Change in the Conway Clinical Scale Score From Baseline to Final Evaluation

Mean Change from Baseline to Final Evaluation in the Per Protocol population assessed by the Conway Clinical Scale. Assessment of the following: Wheezing, Accessory Muscle Use and Pulse Frequency in a 0 to 3 point scale according to severity for a minimum of 0 points and a total of 9 points in a very severe clinical case. (NCT00460577)
Timeframe: Baseline,4 hours

Interventionscore on a scale (Mean)
Formoterol (Foradil®)-3.18
Fenoterol 0.5 mg + Berodual®-3.04

[back to top]

Pharmacoeconomic Analysis

Pharmacoeconomic analysis comparing the mean direct costs (total cost per prescription) of treatment with Formoterol (Foradil®) to treatment with Fenoterol 0.5 mg + Berodual®. (NCT00460577)
Timeframe: 4 hours

InterventionCost in US Dollars (Mean)
Formoterol (Foradil®)9.21
Fenoterol 0.5 mg + Berodual®25.67

[back to top]

Absolute Change in Morning Peak Flow

Absolute change in morning peak flow at the end of the 16-week study period compared with baseline (last two weeks of run-in). Peak flow measurement is a test to measure air flowing out of the lung. (NCT00521222)
Timeframe: Up to 16 weeks from baseline

InterventionL/min (Mean)
Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA-15.7
Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA8.4
Arg/Arg Genotype on Fluticasone HFA-5.6
Gly/Gly Genotype on Fluticasone HFA-14.4

[back to top]

Change in Asthma Symptom Score

Asthma symptom score measures asthma symptoms on a scale from 0 to 3. 0 = No asthma symptoms; 1 = 1-3 asthma episodes each lasting 2 hours or less, all mild; 2= 4 or more asthma episodes that interfered with activity, play, school, or sleep for less than 2 hours; 3= 1 or more asthma episodes lasting longer than 2 hours, or resulting in shortening normal activity, or seeing a doctor, or going to a hospital. A higher score indicates a worse outcome. (NCT00521222)
Timeframe: Up to 16 weeks from baseline

Interventionscore on a scale (Mean)
Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA0.3
Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA-1.2
Arg/Arg Genotype on Fluticasone HFA0.4
Gly/Gly Genotype on Fluticasone HFA0.5

[back to top]

Change in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted Pre-Bronchodilator

Change in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted Pre-Bronchodilator as measured by spirometry (NCT00521222)
Timeframe: Up to 16 weeks from baseline

InterventionPercent Predicted (Mean)
Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA-1.0
Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA-2.5
Arg/Arg Genotype on Fluticasone HFA-3.8
Gly/Gly Genotype on Fluticasone HFA-3.3

[back to top]

Change in Forced Expiratory Volume in 1 Second (FEV1) Post-Bronchodilator

Change in Forced Expiratory Volume in 1 Second (FEV1) Post-Bronchodilator as measured by spirometry (NCT00521222)
Timeframe: Up to 16 weeks from baseline

InterventionLiter (Mean)
Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA0.02
Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA-0.07
Arg/Arg Genotype on Fluticasone HFA-0.11
Gly/Gly Genotype on Fluticasone HFA-0.07

[back to top]

Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-Bronchodilator

Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-Bronchodilator as measured by spirometry (NCT00521222)
Timeframe: Up to 16 weeks from baseline

InterventionLiter (Mean)
Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA-0.03
Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA-0.08
Arg/Arg Genotype on Fluticasone HFA-0.12
Gly/Gly Genotype on Fluticasone HFA-0.11

[back to top]

Change in FEV-1 % Predicted Over Time

Primary Outcome- the difference in FEV-1at 60 minutes between participants who received Levalbuterol 1.25 mg x 3 vs participants who received Levalbuterol 1.25 mg x3 + Ipratropium 0.5 mg x3 (NCT00583778)
Timeframe: 60 minutes

Interventionpercentage of FEV-1 predicted (Median)
Levalbuterol45
Levalbuterol Plus Ipratropium47

[back to top]

Number of Participants With Bronchodilation

Measure FEV-1 in participants immediately prior to treatment and 60 minutes after final treatment to determine improvement in bronchodilation after 1.25mg nebulized levalbuterol + 0.5mg nebulized ipratropium administered every 20 minutes for a total of 3 doses versus bronchodilation after 1.25mg nebulized levalbuterol administered every 20 minutes for a total of 3 doses. FEV-1 measurements were obtained using a hand held spirometer. A difference in 12% of median FEV-1 measures between the two groups was considered clinically significant. Patients were called 14 days after their ED visit to assess relapse or recurrence of acute asthma exacerbation. In addition, a chart review was performed to assess relapse or recurrence of acute asthma exacerbation, as well as determine hospital length of stay in those patients who required admission after the initial visit. (NCT00583778)
Timeframe: FEV-1 measured Immediately before treatment dose 1 & 60 minutes after completion of treatment dose 3. Assessment of relapse or recurrence were determined at day 14 after the ED visit.

InterventionParticipants (Count of Participants)
Levalbuterol74
Levalbuterol Plus Ipratropium67

[back to top]

Hospitalization

(NCT00588406)
Timeframe: 6 hours

Interventionpercentage of participants (Number)
Budesonide39
Placebo39

[back to top]

FEV1 Percent Predicted

(NCT00588406)
Timeframe: 4 hours post-randomization

Interventionpercent predicted of FEV1 (Mean)
Budesonide51.7
Placebo52.6

[back to top]

Actuations Recorded on Patient Diary

(NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg168

[back to top]

Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg4120

[back to top]

Actuations Based on Advancing the Actuation Indicator

Actuations based on advancing the actuation indicator to a zero reading or to the next increment (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg166

[back to top]

Actuations Dispensed

Actuations dispensed is determined by the weight differential of the canister over the course of the study divided by the shot weight (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg159.77

[back to top]

Actuations Registered by the Actuation Indicator

This outcome measure presents the number of actuations (doses) of medication used in the specific time frame as measured by the actuation indicator (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg167

[back to top]

Actuations Registered by the Actuation Indicator and Read by Site Coordinator

(NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg164

[back to top]

Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed

Difference between the number of actuations based on advancing the actuation indicator to a zero reading or to the next increment and the number of actuations dispensed (calculated using weight differential and shot weight) (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg1.71

[back to top]

Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed

Difference between the number of actuations recorded on patient diary and the number of actuations dispensed (calculated using weight differential and shot weight) (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg5.07

[back to top]

Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed

Difference between the number of actuations registered by the actuation indicator and the number of actuations dispensed (calculated using weight differential and shot weight) (NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg1.85

[back to top]

Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed

(NCT00928746)
Timeframe: 21 Days

InterventionCount (Median)
ATROVENT 42mcg3.33

[back to top]

Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg10321

[back to top]

Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg5119

[back to top] [back to top]

Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg11311

[back to top]

Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg6118

[back to top]

Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg3121

[back to top]

Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire

(NCT00928746)
Timeframe: 21 Days

Interventionparticipants (Number)
NoYes
ATROVENT 42mcg6118

[back to top]

Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36

Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied). (NCT01019694)
Timeframe: 36 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat88.2
Combivent Inhalation Aerosol76.9
Atrovent + Albuterol Aerosols80.5

[back to top]

Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48

Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied). (NCT01019694)
Timeframe: 48 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat87.9
Combivent Inhalation Aerosol78.3
Atrovent + Albuterol Aerosols81.7

[back to top]

Physician's Global Evaluation at Week 0

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 0 weeks

Interventionunits on a scale (Mean)
Combivent Respimat5.1
Combivent Inhalation Aerosol4.9
Atrovent + Albuterol Aerosols4.9

[back to top]

Physician's Global Evaluation at Week 12

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 12 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat5.1
Combivent Inhalation Aerosol5.2
Atrovent + Albuterol Aerosols5.0

[back to top]

Physician's Global Evaluation at Week 24

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 24 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat5.1
Combivent Inhalation Aerosol5.2
Atrovent + Albuterol Aerosols5.2

[back to top]

Physician's Global Evaluation at Week 3

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 3 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat5.0
Combivent Inhalation Aerosol5.1
Atrovent + Albuterol Aerosols5.1

[back to top]

Physician's Global Evaluation at Week 36

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 36 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat5.1
Combivent Inhalation Aerosol5.2
Atrovent + Albuterol Aerosols5.2

[back to top]

Physician's Global Evaluation at Week 48

"Physicians evaluated the patient's overall clinical condition on a scale ranging from poor (score 1 or 2) to excellent (score 7 or 8)." (NCT01019694)
Timeframe: 48 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat5.2
Combivent Inhalation Aerosol5.3
Atrovent + Albuterol Aerosols5.1

[back to top]

Change From Baseline in FVC at Week 48

Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 48 (NCT01019694)
Timeframe: baseline, 48 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.35
Combivent Inhalation Aerosol0.30
Atrovent + Albuterol Aerosols0.37

[back to top]

Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization

(NCT01019694)
Timeframe: 48 weeks

,,
Interventionparticipants (Number)
None1 exacerbation2 exacerbations3 or more exacerbations
Atrovent + Albuterol Aerosols146800
Combivent Inhalation Aerosol148600
Combivent Respimat147901

[back to top]

Change From Baseline in FEV1 at Day 1

Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose on test day 1. (NCT01019694)
Timeframe: baseline, day 1

Interventionliters (Least Squares Mean)
Combivent Respimat0.22
Combivent Inhalation Aerosol0.21
Atrovent + Albuterol Aerosols0.21

[back to top]

Change From Baseline in FEV1 at Week 12

Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 12 (NCT01019694)
Timeframe: baseline, 12 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.23
Combivent Inhalation Aerosol0.19
Atrovent + Albuterol Aerosols0.20

[back to top]

Change From Baseline in FEV1 at Week 24

Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 24 (NCT01019694)
Timeframe: baseline, 24 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.20
Combivent Inhalation Aerosol0.21
Atrovent + Albuterol Aerosols0.21

[back to top]

Change From Baseline in FEV1 at Week 48

Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 48 (NCT01019694)
Timeframe: baseline, 48 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.22
Combivent Inhalation Aerosol0.16
Atrovent + Albuterol Aerosols0.23

[back to top]

Change From Baseline in FVC at Day 1

Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose on test day 1. (NCT01019694)
Timeframe: baseline, day 1

Interventionliters (Least Squares Mean)
Combivent Respimat0.37
Combivent Inhalation Aerosol0.34
Atrovent + Albuterol Aerosols0.36

[back to top]

Change From Baseline in FVC at Week 12

Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 12 (NCT01019694)
Timeframe: baseline, 12 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.38
Combivent Inhalation Aerosol0.31
Atrovent + Albuterol Aerosols0.35

[back to top]

Change From Baseline in FVC at Week 24

Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 24 (NCT01019694)
Timeframe: baseline, 24 weeks

Interventionliters (Least Squares Mean)
Combivent Respimat0.33
Combivent Inhalation Aerosol0.35
Atrovent + Albuterol Aerosols0.35

[back to top]

Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

(NCT01019694)
Timeframe: 48 weeks

,,
Interventionparticipants (Number)
None1 exacerbation2 exacerbations3 exacerbations4 exacerbations5 or more exacerbations
Atrovent + Albuterol Aerosols110375200
Combivent Inhalation Aerosol113329000
Combivent Respimat118277311

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 0 weeks

Interventionunits on a scale (Mean)
Combivent Respimat2.8
Combivent Inhalation Aerosol2.7
Atrovent + Albuterol Aerosols2.8

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 12 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat2.8
Combivent Inhalation Aerosol2.9
Atrovent + Albuterol Aerosols2.8

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 24 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat2.7
Combivent Inhalation Aerosol2.8
Atrovent + Albuterol Aerosols2.8

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 3 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat2.7
Combivent Inhalation Aerosol2.7
Atrovent + Albuterol Aerosols2.8

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 36 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat2.7
Combivent Inhalation Aerosol2.8
Atrovent + Albuterol Aerosols2.7

[back to top]

Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48

CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited). (NCT01019694)
Timeframe: 48 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat2.8
Combivent Inhalation Aerosol2.7
Atrovent + Albuterol Aerosols2.9

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 0 (NCT01019694)
Timeframe: 0 weeks

Interventionnumber of puffs (Mean)
Combivent Respimat2.1
Combivent Inhalation Aerosol1.5
Atrovent + Albuterol Aerosols1.9

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 12 (NCT01019694)
Timeframe: 12 weeks

Interventionnumber of puffs (Least Squares Mean)
Combivent Respimat1.9
Combivent Inhalation Aerosol1.9
Atrovent + Albuterol Aerosols1.7

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 24 (NCT01019694)
Timeframe: 24 weeks

Interventionnumber of puffs (Least Squares Mean)
Combivent Respimat2.1
Combivent Inhalation Aerosol2.0
Atrovent + Albuterol Aerosols1.6

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 3 (NCT01019694)
Timeframe: 3 weeks

Interventionnumber of puffs (Least Squares Mean)
Combivent Respimat1.7
Combivent Inhalation Aerosol1.8
Atrovent + Albuterol Aerosols1.7

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 36 (NCT01019694)
Timeframe: 36 weeks

Interventionnumber of puffs (Least Squares Mean)
Combivent Respimat1.9
Combivent Inhalation Aerosol2.1
Atrovent + Albuterol Aerosols1.8

[back to top]

Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48

Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 48 (NCT01019694)
Timeframe: 48 weeks

Interventionnumber of puffs (Least Squares Mean)
Combivent Respimat2.0
Combivent Inhalation Aerosol2.1
Atrovent + Albuterol Aerosols1.8

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 0 weeks

Interventionunits on a scale (Mean)
Combivent Respimat5.8
Combivent Inhalation Aerosol5.9
Atrovent + Albuterol Aerosols5.8

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 12 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat6.2
Combivent Inhalation Aerosol6.0
Atrovent + Albuterol Aerosols5.8

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 24 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat6.3
Combivent Inhalation Aerosol6.0
Atrovent + Albuterol Aerosols5.8

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 3 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat6.2
Combivent Inhalation Aerosol6.1
Atrovent + Albuterol Aerosols5.9

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 36 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat6.4
Combivent Inhalation Aerosol6.0
Atrovent + Albuterol Aerosols5.9

[back to top]

Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48

"Patient satisfaction was assessed by asking: Overall, how satisfied are you with your inhaler?. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied)." (NCT01019694)
Timeframe: 48 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat6.3
Combivent Inhalation Aerosol6.1
Atrovent + Albuterol Aerosols6.0

[back to top]

Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12

Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied). (NCT01019694)
Timeframe: 12 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat85.9
Combivent Inhalation Aerosol78.0
Atrovent + Albuterol Aerosols76.3

[back to top]

Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3

Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied). (NCT01019694)
Timeframe: 3 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat84.7
Combivent Inhalation Aerosol79.4
Atrovent + Albuterol Aerosols77.3

[back to top]

Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24

Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied). (NCT01019694)
Timeframe: 24 weeks

Interventionunit on a scale (Least Squares Mean)
Combivent Respimat86.6
Combivent Inhalation Aerosol77.5
Atrovent + Albuterol Aerosols78.9

[back to top]

Total Number of Participants With Arrhythmias

Documented new arrhythmia occurring during study. (NCT01151579)
Timeframe: Five days

Interventionparticipants (Number)
Nebulized Albuterol 2.5mg2
Levalbuterol 1.253

[back to top]

Arrhythmias

Any new arrhythmia documented in the medical record that occurred between breathing treatments. (NCT01151579)
Timeframe: 15 minutes after each treatment for average of 3 to 5 days

Interventionpercent (Number)
Nebulized Albuterol 2.5mg0.33
Levalbuterol 1.251.3

[back to top]

Heart Rate in Beats Per Minute

Average difference in Heart rate between pre and post breathing treatments (NCT01151579)
Timeframe: Five days

Interventionbpm (Mean)
Nebulized Albuterol 2.5mg-0.16
Levalbuterol 1.251.40

[back to top]

Average Annual Adjusted Post-Index COPD-Related Costs

Medical costs are associated with COPD-related medical care (claims submitted with a primary International Classification of Diseases, 9th Revision, Clinical Modification diagnosis of COPD) and pharmaceutical care (treatment arm medications, oral corticosteroids, oral antibiotics, short-acting beta-agonists, long-acting beta-agonists [LABA], inhaled corticosteroids [ICS], ICS/LABA combinations, etc.. Means are adjusted for age, sex, geographic region, pre-initial treatment comorbidities, and COPD-related utilization. Total costs are the sum of medical care and pharmacy costs. (NCT01331694)
Timeframe: Incurred over the 12 month period after initial treatment arm prescription

,,
InterventionUnited States dollars (Mean)
MedicalPharmacyTotal
Cost Population: FSC10769722068
Cost Population: IP24816142841
Cost Population: TIO14199852408

[back to top]

Time to First Chronic Obstructive Pulmonary Disease (COPD) Event

The first COPD event occurring after 30 days from initial treatment arm prescription was measured. Four categories of COPD events were analyzed; either a hospitalization or emergency department visit; an emergency department visit; an outpatient visit followed by an oral corticosteroid prescription claim within 10 days; an outpatient visit followed by an oral antibiotic prescription claim within 10 days. (NCT01331694)
Timeframe: Anytime from 30 days to 12 months after initial treatment arm prescription

,,
Interventiondays (Mean)
Hospitalization or emergency department visitEmergency department visitOutpatient visit with oral steroid fillOutpatient visit with antibiotic fill
Risk Population TIO321.59328.48331.23326.70
Risk Population: FSC325.17330.24332.74329.96
Risk Population: IP315.89324.47328.23326.73

[back to top] [back to top] [back to top] [back to top] [back to top]

Peak Change From Baseline in IC on Day 7

Peak change from baseline in IC (NCT01350128)
Timeframe: Day 7

InterventionLiters (Least Squares Mean)
PT001 MDI 36 µg BID0.213
PT001 MDI 18 µg BID0.189
PT001 MDI 9 µg BID0.161
PT001 MDI 4.6 µg BID0.192
Ipratropium Bromide HFA Inhalation Aerosol0.191
Placebo MDI BID-0.029

[back to top]

Proportion of Subjects Achieving at Least 12% Improvement in FEV1 on Day 1

Proportion of subjects achieving at least 12% improvement in FEV1 (relative to baseline) (NCT01350128)
Timeframe: Day 1

InterventionPercent (Number)
PT001 MDI 36 µg BID66.67
PT001 MDI 18 µg BID58.70
PT001 MDI 9 µg BID52.27
PT001 MDI 4.6 µg BID60.98
Ipratropium Bromide HFA Inhalation Aerosol77.78
Placebo MDI BID17.39

[back to top]

Time to Onset of Action ( ≥10% Improvement in FEV1) on Day 1

Time to onset of action ( ≥10% improvement in FEV1) (NCT01350128)
Timeframe: Day 1 (15 min, 30 min, 1 hour, 2 hours)

,,,,,
Intervention% of subjects (Number)
15 minutes30 minutes1 hour2 hoursNo onset within 2 hours
Ipratropium Bromide HFA Inhalation Aerosol48259216
Placebo MDI BID7941367
PT001 MDI 18 µg BID3118111327
PT001 MDI 36 µg BID32325230
PT001 MDI 4.6 µg BID252081533
PT001 MDI 9 µg BID197231437

[back to top]

Change From Baseline in 12-hour Post-dose Trough FEV1 on Day 7

Change from baseline in 12-hour post-dose trough FEV1 (NCT01350128)
Timeframe: Day 7

InterventionLiters (Least Squares Mean)
PT001 MDI 36 µg BID0.018
PT001 MDI 18 µg BID0.079
PT001 MDI 9 µg BID0.004
PT001 MDI 4.6 µg BID0.077
Ipratropium Bromide HFA Inhalation Aerosol-0.041
Placebo MDI BID-0.054

[back to top]

Change From Baseline in Morning Pre-dose FEV1 on Day 7

Change from baseline in morning pre-dose FEV1 (NCT01350128)
Timeframe: Day 7

InterventionLiter (Least Squares Mean)
PT001 MDI 36 µg BID0.088
PT001 MDI 18 µg BID0.075
PT001 MDI 9 µg BID0.010
PT001 MDI 4.6 µg BID0.084
Ipratropium Bromide HFA Inhalation Aerosol-0.088
Placebo MDI BID-0.043

[back to top]

FEV1 AUC0-12

FEV1 AUC0-12 following chronic dosing (1 week), normalized. (NCT01350128)
Timeframe: Day 7 ( -1 hour, -30 min, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 5.5 hours, 6.5 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours)

InterventionLiter (Least Squares Mean)
PT001 MDI 36 µg BID1.477
PT001 MDI 18 µg BID1.497
PT001 MDI 9 µg BID1.443
PT001 MDI 4.6 µg BID1.514
Ipratropium Bromide HFA Inhalation Aerosol1.465
Placebo MDI BID1.323

[back to top]

Peak Change From Baseline in FEV1 on Day 1

Highest value of FEV1 post-dose minus baseline on Day 1 (baseline-adjusted) (NCT01350128)
Timeframe: Day 1

InterventionLiter (Least Squares Mean)
PT001 MDI 36 µg BID0.245
PT001 MDI 18 µg BID0.221
PT001 MDI 9 µg BID0.181
PT001 MDI 4.6 µg BID0.204
Ipratropium Bromide HFA Inhalation Aerosol0.250
Placebo MDI BID0.071

[back to top]

Peak Change From Baseline in FEV1 on Day 7

Peak change from baseline in FEV1 (NCT01350128)
Timeframe: Day 7

InterventionLiter (Least Squares Mean)
PT001 MDI 36 µg BID0.242
PT001 MDI 18 µg BID0.224
PT001 MDI 9 µg BID0.223
PT001 MDI 4.6 µg BID0.238
Ipratropium Bromide HFA Inhalation Aerosol0.225
Placebo MDI BID0.070

[back to top]

Peak Change From Baseline in IC on Day 1

Peak change from baseline in Inspiratory Capacity (IC) on Day 1 (mean of 1 and 2 hours post-dose minus baseline on Day 1) (NCT01350128)
Timeframe: Day 1

InterventionLiter (Least Squares Mean)
PT001 MDI 36 µg BID0.240
PT001 MDI 18 µg BID0.276
PT001 MDI 9 µg BID0.185
PT001 MDI 4.6 µg BID0.187
Ipratropium Bromide HFA Inhalation Aerosol0.252
Placebo MDI BID0.040

[back to top]

Pre-dose FVC

Ratio of pre-dose FVC (Forced Vital Capacity) to baseline (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.072
Ipratropium + Theophylline SR1.030

[back to top]

Pre-dose FEV1

Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value (NCT01415518)
Timeframe: Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.079
Ipratropium + Theophylline SR1.009

[back to top]

Post-dose PEF in Whole Treatment Period

Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period (12 weeks)

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR26.507
Ipratropium + Theophylline SR-0.662

[back to top]

Post-dose PEF in Last Week of Treatment

Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR36.612
Ipratropium + Theophylline SR5.100

[back to top]

Post-dose PEF in First Week of Treatment

Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured at 5 minutes after inhalation of study drug in the first week of treatment

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR25.993
Ipratropium + Theophylline SR1.670

[back to top]

Post-dose IC at 60 Minutes

Ratio of post-dose IC at 60 minutes to baseline (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.163
Ipratropium + Theophylline SR1.120

[back to top]

Post-dose FVC at 60 Minutes

Ratio of post-dose FVC at 60 minutes to baseline (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.192
Ipratropium + Theophylline SR1.148

[back to top]

Post-dose FVC at 5 Minutes

Ratio of post-dose FVC at 5 minutes to baseline (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.170
Ipratropium + Theophylline SR1.120

[back to top]

Pre-dose PEF in First Week of Treatment

Change in pre-dose morning PEF from run-in period to first week of treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured before inhalation of study drug in the first week of treatment

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR24.393
Ipratropium + Theophylline SR3.257

[back to top]

Pre-dose IC

Ratio of pre-dose IC (Inspiratory Capacity) to baseline (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.068
Ipratropium + Theophylline SR1.032

[back to top]

Pre-dose PEF in Last Week of Treatment

Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR23.135
Ipratropium + Theophylline SR-2.038

[back to top]

Pre-dose PEF in Whole Treatment Period

Change in pre-dose morning PEF from run-in period to whole treatment period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period (12 weeks)

InterventionL/min (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR21.021
Ipratropium + Theophylline SR-2.023

[back to top]

Use of Reliever Medication During Day in the First Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in to the first week on treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.440
Ipratropium + Theophylline SR-0.097

[back to top]

Use of Reliever Medication During Day in the Last Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in to the last week on treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.398
Ipratropium + Theophylline SR-0.101

[back to top]

Use of Reliever Medication During Day in the Whole Treatment Period

Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period (12 weeks)

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.404
Ipratropium + Theophylline SR-0.061

[back to top]

Use of Reliever Medication During Night in the First Week on Treatment

change in the number of inhalations of reliever medication during day from run-in to the first week on treatment (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.124
Ipratropium + Theophylline SR-0.002

[back to top]

Post-dose FEV1 at 60 Minutes

Ratio of post-dose FEV1 at 60 minutes to baseline value (NCT01415518)
Timeframe: Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.219
Ipratropium + Theophylline SR1.142

[back to top]

Use of Reliever Medication During Night in the Last Week on Treatment

Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the last week on treatment

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.078
Ipratropium + Theophylline SR-0.023

[back to top]

COPD Symptoms Sputum

Change in sputum symptom score (from 0 (none) to 4 (severe)) from run-in period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)

InterventionScore from 0 to 4 (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.332
Ipratropium + Theophylline SR-0.124

[back to top]

COPD Symptoms - Cough

Change in cough symptom score (from 0 (none) to 4 (almost constant)) from run-in period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)

InterventionScore from 0 to 4 (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.441
Ipratropium + Theophylline SR-0.248

[back to top]

COPD Exacerbations

Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms (NCT01415518)
Timeframe: Whole treatment period (12 weeks)

Interventionexacerbations/12 weeks (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR0.069
Ipratropium + Theophylline SR0.121

[back to top]

Change in COPD Symptoms - Breathing

Change in breathing symptom score (from 0 (none) to 4 (severe)) from run-in period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)

InterventionScore from 0 to 4 (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.507
Ipratropium + Theophylline SR-0.229

[back to top]

Use of Reliever Medication During Night in the Whole Treatment Period

Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period (NCT01415518)
Timeframe: Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the whole treatment period (12 weeks)

Interventiontimes/day (Least Squares Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR-0.086
Ipratropium + Theophylline SR0.020

[back to top]

Post-dose FEV1 at 5 Minutes

Ratio of post-dose FEV1 at 5 minutes to baseline value (NCT01415518)
Timeframe: Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug

InterventionRatio (Geometric Mean)
Symbicort Turbuhaler + Ipratropium + Theophylline SR1.179
Ipratropium + Theophylline SR1.106

[back to top]

Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines (NCT01426009)
Timeframe: Day 1 and Day 7

,,,,,,
Interventionliters (Mean)
Day 1Day 7
EP-101 Via Nebulizer (eFlow®) 200 mcg1.4551.453
EP-101 Via Nebulizer (eFlow®) 25 mcg1.4691.482
EP-101 Via Nebulizer (eFlow®) 50 mcg1.4981.496
EP-101 Via Nebulizer (eFlow®)100 mcg1.4431.462
Ipratropium Bromide Inhalation Solution1.6011.594
Placebo1.3561.348
Tiotropium Bromide Via (Spiriva® Handihaler®)1.4341.475

[back to top]

Rescue Medication Use

Mean number of puffs of daily rescue medication (NCT01426009)
Timeframe: Day 1 through Day 7

Interventionaverage daily number of puffs (Mean)
EP-101 Via Nebulizer (eFlow®) 25 mcg1.34
EP-101 Via Nebulizer (eFlow®) 50 mcg1.11
EP-101 Via Nebulizer (eFlow®)100 mcg1.48
EP-101 Via Nebulizer (eFlow®) 200 mcg1.29
Ipratropium Bromide Inhalation Solution1.42
Tiotropium Bromide Via (Spiriva® Handihaler®)1.33
Placebo1.59

[back to top]

Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours post dose for Day 1 and Day 7 within each Treatment Period. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period. Change from baseline was calculated as the trough FEV1 value minus the baseline for Day 1 and Day 7. (NCT01426009)
Timeframe: Day 1 and Day 7

,,,,,,
Interventionliters (Mean)
Trough FEV1 - day 1Trough FEV1 - day 7
EP-101 Via Nebulizer (eFlow®) 200 mcg0.06320.0840
EP-101 Via Nebulizer (eFlow®) 25 mcg0.04770.0478
EP-101 Via Nebulizer (eFlow®) 50 mcg0.10090.0699
EP-101 Via Nebulizer (eFlow®)100 mcg0.06480.0666
Ipratropium Bromide Inhalation Solution0.09330.0292
Placebo0.0301-0.155
Tiotropium Bromide Via (Spiriva® Handihaler®)0.07400.0564

[back to top]

Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests

AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. Vital signs were performed during the screening period to confirm study eligibility and at the final study visit. ECGs were performed during the screening period to confirm study eligibility. Vital signs and ECG were additionally collected within 30 minutes pre-dose; and 30 minutes, and 1, 2, 4, 6, 12 hours, and 23 hours 45 minutes post-dose within each treatment period. Clinical laboratory assessments were conducted during the screening period, at each study visit during each treatment period, and at the final study visit. (NCT01426009)
Timeframe: Day 1 through Day 7

,,,,,,
InterventionParticipants (Count of Participants)
Treatment emergent AEsClinical signicant abnormal vital signsClinically significant abnormal ECG values Day 1Clinically significant abnormal ECG values Day 7Clinicall significant abnormal lab valuesday1-day7
EP-101 Via Nebulizer (eFlow®) 200 mcg26011112
EP-101 Via Nebulizer (eFlow®) 25 mcg2301071
EP-101 Via Nebulizer (eFlow®) 50 mcg230750
EP-101 Via Nebulizer (eFlow®)100 mcg2821382
Ipratropium Bromide Inhalation Solution191531
Placebo251673
Tiotropium Bromide Via (Spiriva® Handihaler®)120880

[back to top]

Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized FEV1 AUC(0-12hr and 12-24hr) on Day 1 and Day 7 was calculated using the trapezoidal rule from the changes in FEV1 at Day 1 and Day 7, respectively, from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval. (NCT01426009)
Timeframe: Day 1 and Day 7

,,,,,,
Interventionliters (Mean)
AUC 0-12 on Day 1AUC 12-24 on Day 1AUC 0-24 on Day 1AUC 0-12 on Day 7AUC 12-24 on Day 7AUC 0-24 on Day 7
EP-101 Via Nebulizer (eFlow®) 200 mcg0.17200.06450.11940.14380.06140.1030
EP-101 Via Nebulizer (eFlow®) 25 mcg0.10010.00390.05250.10340.01120.0579
EP-101 Via Nebulizer (eFlow®) 50 mcg0.15200.06810.11070.14110.05400.0980
EP-101 Via Nebulizer (eFlow®)100 mcg0.14140.04130.09190.13290.02780.0812
Ipratropium Bromide Inhalation Solution0.19900.09870.14960.16030.03570.1009
Placebo0.0130-0.0245-0.0073-0.00980.0698-0.0395
Tiotropium Bromide Via (Spiriva® Handihaler®)0.12130.04990.08720.12560.02830.0776

[back to top]

Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Clinically meaningful is defined as when the change from baseline (mean of the two pre-dose values at Day 1) in 24 hour trough FEV1 on a SUN-101 treatment is more than 100 mL compared to the mean change in trough FEV1 from all subjects on the placebo treatment. (NCT01426009)
Timeframe: Day 1 and Day 7

,,,,,
Interventionnumber of participants (Number)
Day 1Day 7
EP-101 Via Nebulizer (eFlow®) 200 mcg2437
EP-101 Via Nebulizer (eFlow®) 25 mcg1829
EP-101 Via Nebulizer (eFlow®) 50 mcg2930
EP-101 Via Nebulizer (eFlow®)100 mcg2434
Ipratropium Bromide Inhalation Solution2427
Tiotropium Bromide Via (Spiriva® Handihaler®)2637

[back to top]

Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)

percentage of subjects with clinically meaningful change from pre-dose in trough FEV1 on Day 1 and Day 7 Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. (NCT01426009)
Timeframe: Day 1 and Day 7

,,,,,
Interventionpercentage of participants (Number)
Day 1Day 7
EP-101 Via Nebulizer (eFlow®) 200 mcg35.351.4
EP-101 Via Nebulizer (eFlow®) 25 mcg25.040.3
EP-101 Via Nebulizer (eFlow®) 50 mcg38.740.0
EP-101 Via Nebulizer (eFlow®)100 mcg32.046.6
Ipratropium Bromide Inhalation Solution33.837.5
Tiotropium Bromide Via (Spiriva® Handihaler®)34.748.7

[back to top]

Percentage of Days for Which Participants Achieved a >=12% and 200 Milliliter (mL) Increase From Baseline in FEV1

FEV1 is the maximal amount of air that can be forcefully exhaled in one second. During each study period, pre- and post-bronchodilator spirometry for evaluation of FEV1 was performed at study visits as follows: approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). (NCT01691482)
Timeframe: up to 35 days

,
Interventionpercentage of days (Mean)
Albuterol/Salbutamol (A/S) alone, 1 hourA/S followed by ipratropium, 2 hoursIpratropium alone, 1 hourIpratropium followed by A/S, 2 hours
Albuterol/Salbutamol Followed by Ipratropium58.471.7NANA
Ipratropium Follwed by Albuterol/SalbutamolNANA55.469.1

[back to top]

Percentage of Days for Which Participants Achieved a Threshold Increase From Baseline in FEV1 of 100 mL, 200 mL, and 250 mL

FEV1 is the maximal amount of air that can be forcefully exhaled in one second. During each study period, pre- and post-bronchodilator spirometry for evaluation of FEV1 was performed at study visits as follows: approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). (NCT01691482)
Timeframe: up to 35 days

,
Interventionpercentage of days (Mean)
A/S alone, 1 hour, 100 mLA/S followed by ipratropium, 2 hours, 100 mLIpratropium alone, 1 hour, 100 mLIpratropium followed by A/S, 2 hours, 100 mLA/S alone, 1 hour, 200 mLA/S followed by ipratropium, 2 hours, 200 mLIpratropium alone, 1 hour, 200 mLIpratropium followed by A/S, 2 hours, 200 mLA/S alone, 1 hour, 250 mLA/S followed by ipratropium, 2 hours, 250 mLIpratropium alone, 1 hour, 250 mLIpratropium followed by A/S, 2 hours, 250 mL
Albuterol/Salbutamol Followed by Ipratropium81.685.2NANA59.272.7NANA45.964.0NANA
Ipratropium Follwed by Albuterol/SalbutamolNANA72.981.2NANA56.070.5NANA45.859.6

[back to top]

The Maximal Bronchodilator Response for the First Administered Agent

The maximal bronchodilator response for the first administered agent is defined as the FEV1 (the maximal amount of air that can be forcefully exhaled in one second) 1 hour post-dose of the first bronchodilator minus the pre-dose. The maximal bronchodilator response for the second agent is defined as the FEV1 1 hour post-dose of the second bronchodilator minus the FEV1 at 1 hour post-dose of the first bronchodilator. The maximal bronchodilator response for the combination is defined as the FEV1 (the maximal amount of air that can be forcefully exhaled in one second) at 1 hour post-administration of the second bronchodilator minus the corresponding pre-dose FEV1. Derived FEV1 response is FEV1 change from 0 hours (0H) for the first agent assessment (at 1 hour [1H]); change from 1H for the second agent assessment (at 2 hours [2H]); and change from 0H for the combination assessment (at 2H). Data were adjusted for FEV1, smoking status, and center. (NCT01691482)
Timeframe: up to 10 days

InterventionLiters (Least Squares Mean)
First agent, albuterol/salbutamol (A/S)First agent, ipratropiumSecond agent, A/SSecond agent, ipratropiumA/S followed by ipratropiumIpratropium followed by A/S
All Randomized Participants0.2690.2430.0940.0940.3630.337

[back to top]

Variability in Daily FEV1, Estimated by Coefficient of Variation

FEV1 is the maximal amount of air that can be forcefully exhaled in one second. During each study period, pre- and post-bronchodilator spirometry for evaluation of FEV1 was performed at study visits as follows: prior to administration of the first short-acting bronchodilator, approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). Variability in daily FEV1 was measured as the fluctuation around the mean FEV1 data collected from Day 1 to Day 10. Variability was measured by the coefficient of variation (CV) and the half range. The CV is the dispersion of the data around the mean, whereas the half range method is the difference between the maximum and minimum FEV1 values. (NCT01691482)
Timeframe: up to 10 days

,
InterventionLiters (Mean)
Pre-dose/non-bronchodilatorAlbuterol/Salbutamol (A/S) alone, 1 hourA/S followed by ipratropium, 2 hoursIpratropium alone, 1 hourIpratropium followed by A/S, 2 hours
Albuterol/Salbutamol Followed by Ipratropium0.0810.0590.054NANA
Ipratropium Followed by Albuterol/Salbutamol0.079NANA0.0720.063

[back to top]

Variability in Daily FEV1, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum Values)

FEV1 is the maximal amount of air that can be forcefully exhaled in one second. During each study period, pre- and post-bronchodilator spirometry for evaluation of FEV1 was performed at study visits as follows: prior to administration of the first short-acting bronchodilator, approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). Variability in daily FEV1 was measured as the fluctuation around the mean FEV1 data collected from Day 1 to Day 10. Variability was measured by the coefficient of variation (CV) and the half range. The CV is the dispersion of the data around the mean, whereas the half range method is half the difference between the maximum and minimum FEV1 values. (NCT01691482)
Timeframe: up to 10 days

,
InterventionLiters (Mean)
Pre-dose/non-bronchodilatorAlbuterol/Salbutamol (A/S) alone, 1 hourA/S followed by ipratropium, 2 hoursIpratropium alone, 1 hourIpratropium followed by A/S, 2 hours
Albuterol/Salbutamol Followed by Ipratropium0.1360.1250.122NANA
Ipratropium Followed by Albuterol/Salbutamol0.135NANA0.1450.137

[back to top]

Variability in Daily IC, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum)

IC is the the total amount of air that can be drawn into the lungs after normal expiration. During each study period, pre- and post-bronchodilator spirometry for evaluation of IC was performed at study visits as follows: prior to administration of the first short-acting bronchodilator, approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). Variability in daily IC was measured as the fluctuation around the mean IC data collected from Day 1 to Day 10. Variability was measured by the coefficent of variation (CV) and the half range. The CV is the dispersion of the data around the mean, whereas the half range method is half the difference between the maximum and minimum IC values. (NCT01691482)
Timeframe: up to 10 days

,
InterventionLiters (Mean)
Pre-dose/non-bronchodilatorAlbuterol/Salbutamol (A/S) alone, 1 hourA/S followed by ipratropium, 2 hoursIpratropium alone, 1 hourIpratropium followed by A/S, 2 hours
Albuterol/Salbutamol Followed by Ipratropium0.2250.2290.233NANA
Ipratropium Followed by Albuterol/Salbutamol0.236NANA0.2350.221

[back to top]

Variability in Daily Inspiratory Capacity (IC), Estimated by Coefficient of Variation

IC is the the total amount of air that can be drawn into the lungs after normal expiration. During each study period, pre- and post-bronchodilator spirometry for evaluation of IC was performed at study visits as follows: prior to administration of the first short-acting bronchodilator, approximately 1 hour after administration of the first bronchodilator (1 hour), and approximately 1 hour after administration of the second short-acting bronchodilator (2 hours). Variability in daily IC was measured as the fluctuation around the mean IC data collected from Day 1 to Day 10. Variability was measured by the coefficent of variation (CV) and the half range. The CV is the dispersion of the data around the mean, whereas the half range method is the difference between the maximum and minimum IC values. (NCT01691482)
Timeframe: up to 10 days

,
InterventionLiters (Mean)
Pre-dose/non-bronchodilatorAlbuterol/Salbutamol (A/S) alone, 1 hourA/S followed by ipratropium (A+I), 2 hoursIpratropium alone, 1 hourIpratropium followed by A/S (I+A), 2 hours
Albuterol/Salbutamol Followed by Ipratropium0.0780.0690.070NANA
Ipratropium Followed by Albuterol/Salbutamol0.083NANA0.0720.066

[back to top]

Asthma Control Test

The primary symptomatic measure, the Asthma Control Test (ACT), has been shown to be valid for measuring poor asthma control in asthmatic children and non-smoking adults. The ACT is a tool developed by Nathan and collaborators a decade ago for evaluating asthma control. It consists of five questions with five possible answers each. A maximum score of 25 points indicates complete asthma control. A score between 20 and 24 represents partially controlled asthma, while a score 19 or below indicates poorly controlled asthma and a score <16 indicates uncontrolled asthma. The minimally important clinical difference has been determined to be 3. (NCT01696214)
Timeframe: Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and at follow-up visit 1 month off study drug. Median scores over the 24 weeks of treatment were compared.

Interventionunits on a scale (Median)
Ipratropium17.5
Theophylline13
Montelukast12
Fluticasone 250 mg/Salmeterol 50mg10

[back to top]

Percent (%) Perdicted FEV1 Changes

Physiologic measures of % predicted FEV1 (NCT01696214)
Timeframe: Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks. Median scores over the 24 weeks of treatment were compared

Interventionpercent predicted FEV1 (Median)
Ipratropium-1.62
Theophylline4.73
Montelukast0.87
Fluticasone 250 mg/Salmeterol 50mg-5.71

[back to top]

The Asthma Symptom Utility Index (ASUI)

The Asthma Symptom Utility Index (ASUI), an important secondary outcome in the proposed full-scale TOM Trial, has also been shown to be useful in tracking the frequency and severity of asthma-related symptoms in non-smoking asthmatics. ASUI is a brief, interviewer-administered, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects. 11 items are reviewed, with 2-week recall to assess four symptoms (cough, wheeze, shortness of breath, and awakening at night) and medication side-effects each on two dimensions (frequency and severity). 4-point Likert scale is used to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe). Scores range from 0 (worst possible symptoms) to 1 (no symptoms). The change between two time points, initial visit and after 24 weeks of treatment, is reported. The median value is reported with the standard deviation. (NCT01696214)
Timeframe: Outcome measure was assessed at the initial visit, at randomization following a wash-in period of 1 month, monthly for 24 weeks and a follow-up visit 1 month off study drug. Median scores, change from initial visit and end of treatment, were compared

Interventionunits on a scale (Median)
Ipratropium0.16
Theophylline0.24
Montelukast0.14
Fluticasone 250 mg/Salmeterol 50mg0.13

[back to top]

Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Arterial Oxygen Pressure (PaO2) Value

Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment day 3): arterial oxygen pressure (PaO2) value (NCT01943552)
Timeframe: Baseline and Treatment day 3

InterventionmmHg (Least Squares Mean)
Nebulized Ipratropium Bromide3.2
Placebo0.5

[back to top]

Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Oxygen Saturation

Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment day 3): Oxygen saturation (NCT01943552)
Timeframe: Baseline and Treatment day 3

InterventionPercentage of Oxygen (Least Squares Mean)
Nebulized Ipratropium Bromide0.6
Placebo0.3

[back to top]

Change of Forced Expiratory Volume in 1 Second (FEV1) From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery

Change of forced expiratory volume in 1 second (FEV1) from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment day 3). Measurements of FEV1 were performed using calibrated electronic spirometers. Equipment and techniques should conform to American Thoracic Society (ATS) criteria (P05-12782). At screening visit, pulmonary function testing (PFT) was performed at baseline and repeated 30 minutes following inhalation of 4 puffs of salbutamol hydrofluoroalkanes metered-dose inhaler (HFA MDI). At treatment day 3, pulmonary function testing was performed 60 minutes following the inhalation of investigational drug. Spirometry was conducted with the patient in a seated position having abstained from medications. The best of three efforts was defined as the highest FEV1 each obtained on any of three efforts meeting the ATS criteria and it was selected regardless of whether they came from different spirometric manoeuvres or the same manoeuvre. (NCT01943552)
Timeframe: Baseline and Treatment day 3

Interventionml (Least Squares Mean)
Nebulized Ipratropium Bromide169.9
Placebo15.0

[back to top]

Main Post-operative Pulmonary Complications (Including Pneumonia, Atelectasis and Acute Respiratory Failure) Within Three Weeks After the Surgery

Number of patients with at least one main post-operative pulmonary complications (including pneumonia, atelectasis and acute respiratory failure) within three weeks after the surgery. Post-operative pneumonia was defined by the presence of the following criteria: persistent lung infiltrate on chest X-ray or chest computerized tomography (CT)-scan, white blood cell count >10,000 /mm3 and fever. Post-operative atelectasis was diagnosed by presence of atelectasis affecting one lobe or several lobes in chest X-ray test or chest CT-scan. Post-operative acute respiratory failure was defined by the presence of: PaO2 < 60 mmHg and/or PaCO2 > 50 mmHg while breathing air or other evidences which were considered as respiratory failure by investigators. (NCT01943552)
Timeframe: From surgery to 3 weeks post surgery, up to 21 days

InterventionParticipants (Number)
Nebulized Ipratropium Bromide8
Placebo14

[back to top]

Change of Forced Vital Capacity (FVC) From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery

Change of forced vital capacity (FVC) from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment day 3). Measurements of FVC were performed using calibrated electronic spirometers. Equipment and techniques should conform to American Thoracic Society (ATS) criteria (P05-12782). At Visit 1, pulmonary function testing (PFT) was performed at baseline and repeated 30 minutes following inhalation of 4 puffs of salbutamol hydrofluoroalkanes metered-dose inhaler (HFA MDI). At Visit 3, pulmonary function testing was performed 60 minutes following the inhalation of investigational drug. Spirometry was conducted with the patient in a seated position having abstained from medications. The best of three efforts was defined as the highest FVC each obtained on any of three efforts meeting the ATS criteria and it was selected regardless of whether they came from different spirometric manoeuvres or the same manoeuvre. (NCT01943552)
Timeframe: Baseline and Treatment day 3

Interventionml (Least Squares Mean)
Nebulized Ipratropium Bromide59.4
Placebo8.5

[back to top]

Change of Blood Gas Analyses From Pre-bronchodilator at Baseline to Post-nebulization One Day Before the Surgery: Arterial Carbon Dioxide Pressure (PaCO2) Value

Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment day 3): arterial carbon dioxide pressure (PaCO2) value (NCT01943552)
Timeframe: Baseline and Treatment day 3

InterventionmmHg (Least Squares Mean)
Nebulized Ipratropium Bromide-0.1
Placebo-0.5

[back to top]

Change in Forced Expiratory Volume (FEV) From Baseline

Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation. (NCT01987219)
Timeframe: Pre and 30 post study drug admistration

Interventionpercentage change from baseline (Mean)
Albuterol-sulphate7.69
Ipratropium-bromide (Atrovent ®)4.81
Placebo-0.9

[back to top]

Change in Forced Expiratory Flow Between 25-75% (FEF25-75)

FEF25-75 is measured in liters of air per second at 25-75% (NCT01987219)
Timeframe: pre and 30 minutes post intervention

Interventionpercentage change from baseline (Mean)
Albuterol-sulphate14.7
Ipratropium-bromide (Atrovent ®)11.5
Placebo-2.99

[back to top]

Change From Baseline of Forced Vital Capacity

FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function. (NCT01987219)
Timeframe: Pre and 30 minutes post study drug administration

Interventionpercentage change from baseline (Mean)
Albuterol-sulphate5.5
Ipratropium-bromide (Atrovent ®)4.7
Placebo0.9

[back to top]

Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline

The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s). (NCT01987219)
Timeframe: Pre and 30 minutes post study drug administration

Interventionpercentage change from baseline (Mean)
Albuterol-sulphate-22.7
Ipratropium-bromide (Atrovent ®)-19.5
Placebo-1.1

[back to top]

Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo

(NCT03064113)
Timeframe: 12 hr and 24 hr

,,,
InterventionmL (Least Squares Mean)
FEV1 at 12hrFEV1 at 24 hr
Ipratropium 500 μg1534.51509.6
Placebo1519.21533.8
TD-4208 350 μg1631.71636.6
TD-4208 700 μg1642.61670.4

[back to top]

Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo

(NCT03064113)
Timeframe: 12 hr and 24 hr

,,,
Interventionhr*mL (Least Squares Mean)
AUC 0-12 hrsAUC 0-24 hrs
Ipratropium 500 μg287.7271.7
Placebo262.1261.2
TD-4208 350 μg288.5281.3
TD-4208 700 μg291.2286.6

[back to top]

Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline

(NCT03064113)
Timeframe: From predose to 25 hours postdose

InterventionmL (Least Squares Mean)
Placebo1708.0
TD-4208 700 μg1877.3
TD-4208 350 μg1881.8
Ipratropium 500 μg1883.6

[back to top]

Area Under the Forced Vital Capacity (FVC) vs. Time Curve

(NCT03064113)
Timeframe: 0-24 hours

Interventionhr*mL (Least Squares Mean)
Placebo74168.1
TD-4208 700 μg80057.0
TD-4208 350 μg78143.6
Ipratropium 500 μg76822.7

[back to top] [back to top] [back to top]

Forced Vital Capacity (FVC)

(NCT03064113)
Timeframe: From predose to 25 hours postdose

,,,
InterventionmL (Mean)
Predose15 min30 min45 min1 hour2 hours3 hours4 hours6 hours8 hours10 hours11 hours12 hours14 hours22 hours23 hours24 hours25 hours
Ipratropium 500 μg2959.43339.73399.43394.13379.43441.63474.13368.83295.33305.23180.33162.33131.33123.83010.03006.33031.63219.4
Placebo2941.92873.42944.72927.22968.13062.53122.23177.83192.63197.22958.73156.23092.83114.43033.82999.73018.13172.8
TD-4208 350 μg2986.73119.33262.23328.83361.93408.83420.33340.93220.63301.63339.43295.53265.13319.13147.23232.23243.13295.2
TD-4208 700 μg2949.13166.93263.83324.73269.43363.13430.43386.33442.83259.43335.33296.23229.43333.13314.53349.43345.63392.5

[back to top]

Change in Pulmonary Inspiratory Force (PIF) From Baseline at 90 Days - R -5 (High Resistance Inhalers)

Pulmonary inspiratory force (PIF) from hospital baseline between the two arms for the duration of the 90 day study. (NCT03219866)
Timeframe: Baseline and 90 days

InterventioncmH2O (Mean)
Nebulizers43.7
Dry Powder Inhaler46.5

[back to top]

Change in Pulmonary Inspiratory Force (PIF) From Baseline at 90 Days - R -2 (Low to Medium Resistance Inhalers)

Pulmonary inspiratory force (PIF) from hospital baseline between the two arms for the duration of the 90 day study. (NCT03219866)
Timeframe: Baseline and 90 days

InterventioncmH2O (Mean)
Nebulizers73.9
Dry Powder Inhaler74.2

[back to top]

Symptom Control Measured by The Modified Medical Research Council Dyspnea Scale (mMRC)

The Modified Medical Research Council Dyspnea Scale, or MMRC, uses a simple grading system to assess a patient's level of dyspnea -- shortness of breath. The scale goes from 0-4 with a 0 = I only get breathless with strenuous exercise, 1 = I get short of breath when hurrying on level ground or walking up a slight hill, 2 = On level ground, I walk slower than people of the same age because of breathlessness or have to stop for breath when walking at my own pace, 3 = I stop for breath after walking about 100 yards or after a few minutes on level ground, and 4 = I am too breathless to leave the house or I am breathless when dressing. 4 would represent the worst outcome. (NCT03219866)
Timeframe: 90 Days

Interventionscore on a scale (Mean)
Nebulizers2.1
Dry Powder Inhaler1.6

[back to top]

Unscheduled Clinic or ER Visits

Compare the number of unscheduled clinic or ER visits between the two arms after 90 days of using each device (NCT03219866)
Timeframe: 90 Days

Interventionnumber of visits (Number)
Nebulizers4
Dry Powder Inhaler4

[back to top]

Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ)

Scores range from 0 to 100, with higher scores indicating more limitations - Symptoms component (frequency & severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall (NCT03219866)
Timeframe: 90 Days

Interventionscore on a scale (Mean)
Nebulizers49.3
Dry Powder Inhaler43.7

[back to top]

Number of Deaths

(NCT03219866)
Timeframe: 90 days

InterventionParticipants (Count of Participants)
Nebulizers1
Dry Powder Inhaler1

[back to top]

COPD and All-Cause Hospital Readmissions After 90 Days

Compare the number of hospital readmissions between the two arms after 90 days of using each device. (NCT03219866)
Timeframe: 90 Days

Interventionnumber of readmissions (Number)
Nebulizers2
Dry Powder Inhaler4

[back to top]

COPD and All-Cause Hospital Readmissions After 30 Days

Compare the number of hospital readmissions between the two arms after 30 days of using each device. (NCT03219866)
Timeframe: 30 Days

Interventionnumber of readmissions (Number)
Nebulizers1
Dry Powder Inhaler3

[back to top]

Symptom Control Measured by the COPD Assessment Test (CAT)

The COPD Assessment Test (CAT) is a patient-completed instrument that can quantify the impact of COPD on the patient's health. The CAT is a validated, short (8-item) and simple patient completed questionnaire. The CAT has a scoring range of 0-40 and a difference or change of 2 or more units over 2 to 3 months in a patient suggests a clinically significant difference or change in health status. A score of >30 indicates that COPD has a very high impact on daily life, a score of >20 indicates a high impact, 10-20 is medium impact, <10 is low impact, and 5 is the upper limit for healthy non-smokers. A higher score would represent a poor outcome for this test. (NCT03219866)
Timeframe: 90 Days

Interventionscore on a scale (Mean)
Nebulizers19.2
Dry Powder Inhaler16.5

[back to top]